Ritlecitinib ( PF-06651600 )
Protocol B798106 [ADDRESS_1221038] OF MULTIP LE-DOSE RITLECITINIB ( PF-06651600 )ON THE
PHARMACOKINETICS OF SINGLE -DOSE TOLBUTAMIDE IN HEALTHY 
PARTICIPANT S
Study Intervention Number : PF-06651600
Study Intervention Name: [CONTACT_874394]: 131,[ADDRESS_1221039] Number: 2021- 003611 -25
ClinicalTrials.gov ID: Not Applicable
Protocol Number: B79810 69
Phase: 1
Short Title: Open -Label, 
Fixed- Sequence, 2-P eriod Study  to Evaluate the Effect of 
Multiple -Dose Ritlecitinib on the PK of Tolbutamide
This document and accompanying materials contain confidential information belonging to [COMPANY_007].  Except as 
otherwise agreed to in writing, by [CONTACT_185586] s, you agree to hold this 
information in confidence and not copy or disclose it to others (except where required by [CONTACT_214325] ) or 
use it for unauthorized purposes.  In the event of any actual or suspected breach of this obligation, [COMPANY_007] 
must be promptly notified.

Ritlecitinib ( PF-06651600 )
Protocol B798106 [ADDRESS_1221040] of country  health authorities and IRBs/ECs and any  global protocol administrative 
clarification letter.
Protocol Amendment Summary of Changes Table
Amendment 1 (17- September -2021)
Section # and 
NameDescription of Change Brief Rationale
Section 5.2
Exclusion 
Criteria #17Update E xclusion Criteria #17 to 
“Known participation in a 
clinical trial of ritlecitinib and 
the participant experienced a 
ritlecitinib -related AE that led to 
discontinuation or had a 
ritlecitinib -related SAE.”T
he portion of the exclusion c riterion
that prohibited participation in a 
ritlecitinib study  during the [ADDRESS_1221041] in B7 981069 has been removed. 
The study  team determined that the 
expected follow -up periods included in 
prior ritlecitinib studies that participants 
may be involved in, 
together with the 
screening period into this study , would 
be sufficient to allow for washout of 
ritlecitinib from previous studies and for 
a return of any impacted drug 
metabolizing enzy mes from previous 
studies to their baseline activity .

Ritlecitinib ( PF-06651600 )
Protocol B798106 [ADDRESS_1221042] OF TABLES ................................ ................................ ................................ ..................... 8
1. PROTOCOL  SUMMARY .....................................................................................................9
1.1. Sy nopsis ....................................................................................................................9
1.2. Schema (Not Applicable) ........................................................................................11
1.3.Schedule of Activities .............................................................................................12
2. INTRODUCTION ...............................................................................................................16
2.1. Study  Rationale .......................................................................................................16
2.2. Background .............................................................................................................16
2.2.1. Nonclinical Pharmacology ..........................................................................17
2.2.2. Nonclinical Pharmacokinetics and Metabolism
.........................................17
2.2.3. Nonclinical Safet y
......................................................................................17
2.2.4. Clinical Overview .......................................................................................17
[IP_ADDRESS]. Clinical Overview of Ritlecitinib ..............................................17
[IP_ADDRESS]. PK Overview of Ritlecitinib ......................................................18
2.3. Benefit/Risk Assessment
.........................................................................................20
2.3.1. Risk Assessment
.........................................................................................21
2.3.2. Benefit Assessment .....................................................................................23
2.3.3. Overall Benefit/Risk Conclusion ................................................................23
3. OBJECTI
VES AND EN DPOINTS .....................................................................................23
4. STUDY DESIGN .................................................................................................................23
4.1. Overall Desig n
.........................................................................................................23
4.2. Scientific Rationale for Study  Design .....................................................................24
4.2.1. Diversity  of Study  Population ................................ ................................ ....24
4.2.2. Collection of Retained Research Samples ................................ .................. 24
4.3. Justification for Dose ..............................................................................................25
4.3.1. Justification of Ritlecitinib Dose
................................................................25
4.3.2. Justification of Tolbutamide Dose
..............................................................25
4.4. End of Study  Definition ..........................................................................................25
5. STUDY POPUL ATION
................................ ................................ ................................ ......25
5.1. I nclusion Criteria .....................................................................................................26

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 45.2. Exclusion Criteria ....................................................................................................26
5.3. L ifesty le Considerations ..........................................................................................31
5.3.1. Meals and Dietary  Restrictions ................................ ................................ ...31
5.3.2. Caffeine, Alcohol, and Tobacco .................................................................31
5.3.3. Activity .......................................................................................................32
5.3.4. Contraception ..............................................................................................32
5.3.5. Vaccination
.................................................................................................32
5.4. Scr een Failures ........................................................................................................33
6. STUDY INTERVENTIO N
..................................................................................................33
6.1. Study  Intervention(s) Administered ........................................................................33
6.1.1. Administration ............................................................................................33
6.2. Preparation/Handling/Storage/Accountability ........................................................34
6.2.1. Preparation and Dispensing ........................................................................35
6.3. Measures to 
Minimize Bias: Randomization and Blinding.....................................35
6.3.1. Allocation to Study Intervention ................................................................35
6.4. Study  Intervention Compliance ...............................................................................35
6.5. Dose Modifi cation ...................................................................................................35
6.6. Continued Access to Study  Intervention After the End of the Study ......................36
6.7. Treatment of Overdose
............................................................................................36
6.8. C
oncomitant Therapy..............................................................................................36
6.8.1. Rescue Medicine .........................................................................................37
7. DI SCONTINUATION O F STUDY INTERVENTION AND PARTI CIPANT 
DISCONTINUATION/WI THDRAWAL ...........................................................................37
7.1. Discontinuation of Study  Intervention ....................................................................37
7.2. Participant Discontinuation/Withdrawal From the Study ................................ .......[ADDRESS_1221043] to Follow -
up ....................................................................................................38
8. STUDY ASSESSMENTS AND PROCEDURES ...............................................................39
8.1. Efficacy  Assessments ..............................................................................................40
8.2. Safet y Assessments .................................................................................................40
8.2.1. Phy sical Examinations ................................................................................40
8.2.2. Vital Signs ..................................................................................................41

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Temperature ..............................................................................41
8.2.3. Electrocardiograms
.....................................................................................41
8.2.4. Clinical Safety  Laboratory  Assessments ....................................................42
8.2.5. COVID -19 specific assessments .................................................................43
8.2.6. Estimated Glomerular Filtration Rate .........................................................43
8.2.7. Pregnancy  Testing ......................................................................................43
8.3. Adverse Events and Serious Adverse Events, and Other Safet y Reporting ............44
8.3.1. Time Period and Frequency  for Collecting AE and SAE Information .......44
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety ...............................................45
[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF ...................45
8.3.2. Method of Detecting AEs and SAEs ..........................................................45
8.3.3. Follow -up of AEs and SAEs .......................................................................45
8.3.4. Regulatory
 Reporting Requirements for SAEs ...........................................45
8.3.5. Environmental Exposure, Exposure During Pregnancy  or 
Breastfeeding, and O ccupational Exposure .....................................................46
[IP_ADDRESS]. Exposure During Pregnancy ......................................................46
[IP_ADDRESS]. Exposure During Breastfeeding ................................................48
[IP_ADDRESS]. Occupational Exposure .............................................................48
8.3.6. Cardiovascular and Death Events (Not applicable) ................................ ....48
8.3.7. Disease -Related Events and/or Disease -Related Outcomes Not 
Qualify ingas AEs or SAEs (Not applicable) ..................................................[ADDRESS_1221044] (Not applicable)
..................................48
[IP_ADDRESS]. Lack of Efficacy  (Not applicable) .............................................48
8.3.9. Medical Device Deficiencies (Not applicable)
...........................................49
8.3.10. Medication Errors .....................................................................................49
8.4. Pharmacokinetics ....................................................................................................49
8.5. Genetics ...................................................................................................................50
8.5.1. Specified Genetics ......................................................................................50
8.5.2. Retained Research Samples for Genetics
...................................................51
8.6. Biomarkers ..............................................................................................................51
8.6.1. Retained Research Samples for Biomarkers ...............................................51
8.7. I mmunogenicit y Assessments .................................................................................51

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 68.8. Health Economics ................................ ................................ ................................ ...52
9. STATI STICAL CONSI DERATIONS ................................................................................52
9.1.Statistical Hy potheses .............................................................................................52
9.2. A nalysis Sets ...........................................................................................................52
9.3. Statistical Analy ses.................................................................................................52
9.3.1. General Considerations ...............................................................................53
9.3.2. Primary  Endpoints ......................................................................................53
9.3.3. O ther Endpoints ..........................................................................................54
9.3.4. Other Safet y Analyses ................................................................................54
9.3.5. Other Anal yses............................................................................................54
9.4. I nterim Anal yses.....................................................................................................54
9.5. Sample Size Determination ................................ ................................ ..................... 54
10. SUPPORTING DOCUM ENTATION AND OPERATI ONAL 
CONSI DERATIONS ..........................................................................................................56
10.1. Appendix 1: Regulatory , Ethical, and Study  Oversight Considerations ...............56
10.1.1. Regulatory and Ethical Considerations ....................................................56
[IP_ADDRESS]. Reporting of Safety  Issues and Serious Breaches of the 
Protocol or I CH GCP .........................................................................56
10.1.2. I nformed Consent Process ........................................................................57
10.1.3. Data Protection .........................................................................................57
10.1.4. Committees Structure ...............................................................................58
[IP_ADDRESS]. Data Monitoring Committee ................................ ................... 58
10.1.5. Dissemination of Clinical Study  Data ......................................................58
10.1.6. Data Qualit y Assurance ............................................................................59
10.1.7. Source Documents ................................ ................................ .................... 60
10.1.8. Study  and Site Start and Closure ..............................................................61
10.1.9. Publication Policy
.....................................................................................62
10.1.10. Sponsor’s Qualified Medical Personnel .................................................62
10.2. Appendix 2: Clinical Laboratory  Tests .................................................................64
10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting ................................ ................................ ......66
10.3.1. Definition of AE .......................................................................................66

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 710.3.2. Definition of SAE.....................................................................................67
10.3.3. Recording/Reporting and Follow
-up of AEs and/or SAEs During 
the Active Collection Period ............................................................................68
10.3.4. Reporting of SAEs
....................................................................................72
10.4. Appendix 4: Contraceptive and Barrier Guidance ................................................73
10.4.1. Male Participant Reproductive Inclusion Criteria
....................................73
10.4.2. Female Participant Reproductive Inclusion Criteria .................................73
10.4.3. Woman of Childbearing Potential ............................................................73
10.4.4. Contraception Methods .............................................................................74
10.5. Appendix 5: Genetics ............................................................................................76
10.6. Appendix 6: L iver Safety : Suggested Actions and Follow -up Assessments ........77
10.7. Appendix 7: ECG Findings of Potential Clinical Concern ...................................79
10.8. Appendix 
8: Guidelines for Participant Safety Monitoring and 
Discontinuation ..........................................................................................................81
10.8.1. Participant Safet y Monitoring
...................................................................81
10.8.2. Participant Discontinuation Criteria .........................................................82
10.9.
Appendix 9: Abbreviations ...................................................................................84
11. REFERENCES ..................................................................................................................88

Ritlecitinib ( PF-06651600 )
Protocol B798106 [ADDRESS_1221045] OF TABLES
Table 1. Schedule of Activities ................................ ................................ ............... 12
Table 2. Pharmacokinetic Sampling Schema .........................................................15
Table 3. Treatment Flow Diagram ..........................................................................24
Table 4. Plasma Pharmacokinetic Parameter Definitions
.......................................52
Table 5. Estimated 90% CI s for Different Underlay ing Effects .............................55
Table 6. Protocol -Required Safet y Laboratory  Assessments .................................64

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 91.PROTOCOL SUMMARY 
1.1.Synopsis 
Brief Title: Open -Label, Fixed -sequence, 2-P eriod Study  to Evaluate the Effect of 
Multiple -Dose Ritlecitinib on the PK ofTolbutamide
Rationale
This is a P hase 1,
2-period, multiple -dose, open -label, single fixed sequence study of the 
effect of ritlecitinib on tolbutamide pharmacokinetics in healthy participants. A total of 
approximately  12health ymale and/or female participants will be enrolled in the study  to 
obtain at least [ADDRESS_1221046]. This isanopen -label study not requiring an assessment 
of efficacy  or pharmacody namics markers, but it will include PK estimation DDIs.
Objectives and Endpoints
Objectives Endpoints
Prim ary: Prim ary: 
 To evaluate the effect of multiple -dose ritlecitinib 
(PF-06651600) on the PK of a single, oral dose of 
tolbuta mide in healthy participants. CmaxandAUC inf(if data permit, otherwise AUC last) of 
tolbutamide.
Secondary : Secondary : 
 To evaluate the safety and tolerability of ritlecitinib 
when coadministered with a single dose of 
tolbutamide. Incidence of treatment -emergent adverse events
Other/Exploratory: Other/Exploratory: 
 To characterize the PK of a single oral dose of 
tolbutamide in healthy participants. Plasma tolbutamide PK parameters:T max, AUC last, 
CL/F , Vz/Fand t ½, as data permit.
Overall Design
Brief Summary
This is a P hase 1, 2-period , multiple -dose, open -label, single fixed sequence study of the 
effect of ritlecitinib on tolbutamide pharmacokinetics in healthy participants. A total of 
approximately  12health ymale and/or female participants will be enrolled in the study  to 
obtain at least 10 evaluable participants who complete the study . Participants who withdraw 
from the study  or are considered non-evaluable may  be replaced at the discretion of the 
sponsor .

Ritlecitinib ( PF-06651600 )
Protocol B798106 [ADDRESS_1221047] dose of study  medication. 
Participants will report to the CRU the day  prior to Day 1 dosing (Day  -1) in Period 1 for 
both treatment sequences. Participants will remain in the CRU for a total of 16 days and 
15nights. This includes 4 days and 4 nights (starting the night of admission to the CRU) in 
Period [ADDRESS_1221048] .
Number of Participants
Approximately 12participants will be enrolled to study  intervention.
Note: "Enrolled" means a participant's, or his or her legally  authorized representative’s, 
agreement to participate in a clinical study
 following completion of the informed consent 
process and screening . A participant will be considered enrolled if the informed consent is 
not withdrawn prior to participating in an y stud y activi ty after screening .Potential 
participants who are screened for the purpose of determining eligibility  for the study , but do 
not participate in the study, are not considered enrolled, unless otherwise specified b y the 
protocol.
Intervention Groups and Duration
In Period 1, participants will be dosed with a single administration of tolbutamide [ADDRESS_1221049] Follow-up 
phone call, is approximately up to 11 weeks.

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 11Data Monitoring Committee or Other Independent Oversight Committee : No.
Statistical Methods
There is no formal research hy pothesis to be statistically  tested for this study . The purpose of 
this study  is to estimate the PK effect , as well as safet y and tolerability of multiple -dose 
ritlecitinib with a single, oral dose of tolbuta mide in healthy  participants.
Natural log transformed AUC inf, AUC last, and C maxoftolbutamide will be analy zed using a 
mixed effect model with treatment as a fixed effect and participant as a random effect. 
Estimates of the adjusted mean differences (Test- Reference) and co rresponding 90% CIs will 
be obtained from the model. The adjusted mean differences and 90% CIs for the differences 
will be exponentiated to provide estimates of th e ratio of adjusted geometric means 
(Test/Reference) and 90% CI s for the ratios. 
Tolbutamide alone will be the Reference 
treatment, while the tolbutamide co‑administered with ritlecitinib will be the Test treatment.
1.2.Schema (Not Applicable)

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template (01 March 2021)
Page 121.3. S chedule of Activ ities
The SoA table provides an overview of the protocol visits and procedures. Refer to the STUDY ASSESSMENTS AND 
PROCEDURES section of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol. 
The investigator may  sche dule visits (unplanned visits) in addition to those listed i n the SoA table , in order to conduct evaluations or 
assessments required to protect the well -being of the participant .
Table 1.Schedule of Activities 
Screening Period [ADDRESS_1221050] 
Dosen
Informed consent X
Inclusion/Exclusion 
CriteriaX
CRU confinement X          X
Medical, drug, tobacco 
and alcohol historyX X
Demography X
Complete /limited
physical examinationbX X XoXo
Safety laboratorycX X X X X X
TB screeningdX
Serum FSH 
(postmenopausal women 
only)X
Pregnancy test (for 
WOCBP only)eX X X X
Serology: HBsAg, 
HBcAb, HCV Ab, and 
HIVfX

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template (01 March 2021)
Page 13Table 1. Schedule of Activities 
Screening Period [ADDRESS_1221051] 
Dosen
Collection of baseline
sample for potential viral 
screensgX
Retained Research 
Sample for Genetics 
(Prep D1 )hX
Retained Research 
Sample for Biomarkers 
(Prep B2)hX
Genotypi[INVESTIGATOR_874373]2 C9hX
Urine drug screen X X
COVID -19 testing X X X X
COVID -19 temperature
checkX X X X X X X X X X X X X
COVID -19 check 
questionnaireX X X
Single 12 -Lead ECGiX X X X
Vital signs (supi[INVESTIGATOR_30991], 
pulse rate and oral 
temperature )iX X X X
Contraception check X X X X X
Tolbutamide dosing XjXk
Ritlecitinib QD dosing X X X X Xk
Tolbutamide PK blood 
sample slX X X X
Serious and non -serious 
AE monitoringmX           X X X
Prior/concomitant 
treatment assessmentX           X X
CRU discharge X

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template (01 March 2021)
Page 14Table 1. Schedule of Activities 
Screening Period [ADDRESS_1221052] 
Dosen
a. Day relative to start of study treatment (Day 1).
b. Complete physical examination can be performed either at Screening or Day -[ADDRESS_1221053] 12 hours.
d. TB screening will utilize IGRA. Details of eligibility are described in Appendix 2 .
e. Pregnancy tests will also be done whenever 1 menstrual cycle is missed during the active treatment period (or when potential pregnancy is otherwise suspected) and at the 
end of the study.
f. All participants will undergo screening for Hepatitis B and Hepatitis C for eligibility. Please refer to Appendix 2 for testing algorithm, reflex testing, and full eligibility 
criteria.
g. A serum sample will be collected at baseline and submitted to the central lab. The sample will be stored and analyzed at a la ter date only at the sponsor’s request. For 
example, in certain cases of suspected viral infection (eg, disseminated herpes zoster or varicella), the sponsor may request to analyze the sample to determine if the subject 
had exposure to that virus.
h. If not collected on the designated collection day, collect at the next available time point when biospecimens are being collected in conjunction with a participant visit.
i. ECG and v ital signs will be collected before dosing on Day [ADDRESS_1221054] , the dosing w ill be administered at 
approximately 08:00 ±2hours. Ritlecitinib will be administered first. After swallowing the ritlecitinib dose, tolbutamide should be administered within app roximately [ADDRESS_1221055].
o. Limited physical exam as deemed appropriate by [CONTACT_093] .

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template (01 March 2021)
Page 15Table 2.Pharmacokinetic Sampling Schema
Study Day for Period 1 1 2
Study Day for Period 2 10 11
Hours After Dose 0 0.5 1 2 3 4 5 6 8 12 16 24 36
Tolbutamide administration X
Tolbutamide PK blood sampling XaX X X X X X X X X X X X
Abbreviations: PK = pharmacokinetic.
a. Pre-dose sample.

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 162.INTRODUCTION
Ritlecitinib ( PF-06651600 )is a selective covalent inhibitor of JAK3 and the tyrosine kinase 
expressed in TEC family  kinases and is currently  under development for the treatment of 
AA
, RA , vitiligo, UC, and CD.
2.1.Study Rationale 
The purpose of the study  is to estimate the inductive effect of multiple -dose ritlecitinib on 
single dose PK of tolbutamide .In vitro studies indicated mild induction potential of 
ritlecitinib for CYP3A4 (R 0.08), CYP2B6 (R 0.23), CYP1A2 (R 0.07), CYP2C8 (R 0.06), 
CYP2C9 (R 0.29), and CYP2C19 (R 0.32) enzy mes, where R represents the predicted r atio 
of intrinsic clearance values of a probe substrate for an enzy matic pathway in the absence
and presence of an inducer .The effect of ritlecitinib on CYP3A4 and CYP2B6 was evaluated 
in a drug interaction study  with coadministration of both sensitive CYP3A substrate, 
midazolam, and sensitive CYP2B6 substrate, efavirenz (B7981017), and the results indicated 
that ritlecitinib is a moderate CYP3A inhibitor and does not affect CYP2B6 enzy mes. The 
CYP2C enzy mes are regulated by  [CONTACT_874384] X receptor (PXR) pathw ay, which regulates 
CYP3A enzy mes as well.1Study  B7981017 results implied the net effect of ritlecitinib on 
CYP3A from both enzyme induction and inhibition, and enzy me induction risk of ritlecitinib
through PXR pathway  cannot be completel y ruled out. Therefore, a DDI study  assessing the 
ritlecitinib effect on the in vivo pharmacokinetics of a sensitive CYP2C substrate needs to be 
conducted to rule out an inducive effect on the aforementioned isoenzy mes.
Tolbutamide is a first generation sulphonylurea developed for treatment of diabetes mellitus. 
When administered orally , tolbutamide is readily  absorbed from the gastrointestinal tract. 
Absorption and pharmacody namic effects of tolbutamide are not impacted by  [CONTACT_8208]. 
Detectable levels of tolbutamide are pr esent in the plasma within [ADDRESS_1221056] of PF-06651600 on the pharmacokinetics of tolbutamide .
2.2.Background 
Ritlecitinib is a covalent and irreversible inhibitor of JAK3 with high selectivity  over the 
other 3 JAK isoforms (JAK1, JAK2, and TYK2). Ritlecitinib also inhibits irreversibl y the 
tyrosine kinase expressed in TEC family  kinases with selectivity  over the broader human 
kinome. Treatment with ritlecitinib is expected to inhibit the inflammatory  pathway s 
mediated b y IL-7, IL -15, and IL -21, all implicated in UC, AA, RA, C Dand vitiligo. Due to 
lack of activity  against the other JAK isoforms, ritlecitinib is expected to spare 
immunoregulatory  cytokines such as IL -10, IL -27 and IL -35, which are critical to the 
maintenance of immunosuppressive functions and immune homeostasis.

Ritlecitinib ( PF-06651600 )
Protocol B798106 [ADDRESS_1221057] dose tested, the NOAEL  in the 8-week 
dog stud y was 45 mg/kg/day. In the first 9- month dog study , the NOAEL was 5 mg/kg/day , 
the lowest dose tested, based on the adverse finding of axonal dy strophy  in the brainstem and 
associated waveform defec ts in males and females administered ≥ 20 mg/kg/day , the next 
highest dose used in that study . In the second 9 -month dog toxicity  study , the NOAEL was 
10 mg/kg/day , based on adverse over -immunosuppression and axonal dy strophy  in the CNS 
and PNS at ≥20 mg/kg/day , accompanied by  [CONTACT_798448] (BAEP) at the 
highest dose of 40 mg/kg/day . The 10 mg/kg/day  dose corresponded to a mean AUC 24of 
7940 ng•h/mL and exposure margins were 6.5x and 1.5x the AUC 24at the 50 mg and 200 mg 
clinical doses, respectively .
Further information is available in the current version of the ritlecitinib IB .
2.2.4.
Clinical Overview
[IP_ADDRESS]. Clinical Overview of Ritlecitinib
Ritlecitinib has been explored in health y participants in 14Phase [ADDRESS_1221058] udy, a relative BA study of oral solution formulation of ritlecitinib relative 
to tablets (B7981003), a PK study  in Japanese participants (B7981008), anADME study 
(B7981011), a drug interaction study  with midazolam and efavirenz (B7981017), a drug 
interaction study  with oral hormonal contraceptive for ritlecitinib 200 mg QD (B7981018)
and 50 mg ritlecitinib 50 mg QD (B7981035) , a palatability  study  which investigated the 
palat ability  of oral formulations of ritlecitinib for pediatric use (B7981021) ,a relative 
bioavailability  study  of candidate capsule formulations of ritlecitinib relative to tablets
(B7981022), a drug interaction study  with itraconazole (B7981023), a drug interaction study  
with rosuvastatin ( B7981024) , a drug interaction study  with sumatriptan (B798102 5),a drug 
interaction study  with rifampin (B7981026) , and a PK study  in Chinese
participants 
(B79810 36). Ritlecitinib was also investigated in specific populatio ns of hepatic impairment 
(B7981016) and renal impairment (B7981020) . Ritlecitinib has been investigated in 
2Phase 2 trials in participants with RA (B7981006) and AA (B7981005). There are ongoing 
studies in participants with AA (B7981015 and B7981032), Vit iligo (B7981019), UC 
(B7981005) and CD (B7981007).

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. PK Overview of Ritlecitinib
The PKprofile of ritlecitinib is characterized by  [CONTACT_626523] (Tmaxof ~1 hour) , rapid 
elimination ( t½of ~2 hours) and is approximately  dose proportional. Ritlecitinib has been 
evaluated at single oral doses ranging from 5 mg to 800 mg and multiple oral doses ranging 
from 50 mgto 400 mg QD and at 100 mg and 200 mgBID for 14 days. Even though 
ritlecitinib has a short t ½(~2hours ), steady state generall y appears to be reached by  [CONTACT_2006]  4for 
the QD regimens and Day 6 for the BID regimens based on similar median trough (pre -dose) 
ritlecitinib beyond Day 6.The accumulation ratio for50and 200 mg QD wasalso1.4 and 
1.8 respectivel y, suggesting nonlinear characteristics of ritlecitinib PK . Ritlecitinib is 
primarily  cleared by  [CONTACT_89411]
. Less than 8% of ritlecitinib is excreted unchanged in the 
urine.
[IP_ADDRESS].1. Studies in Healthy Participants
In all [ADDRESS_1221059] an acceptable safet y profile.
Further information is available in the current version of the ritlecitinib IB .
[IP_ADDRESS].2. Phase 2a Study in Rheumatoid Arthritis
The completed Phase 2a study  B7981006 was an 8 -week randomized, double -blind, placebo-
controlled, parallel -group, multi -center study  in participants with moderate -to-severe active 
RA with an inadequate response to methotrexate. A total of 70 participants were randomized 
to study  treatment; 28 participants received placebo and 42 par ticipants received ritlecitinib
200 mg QD . Participants remained on stable background arthritis therap y, which had to 
include methotrexate (supplemented with folic/folinic acid per the local treatment 
guidelines).
Ritlecitinib was determined to be generall y safe and well tolerated in this study. There were 
no deaths or SAEs. TEAEs were numericall y higher in participants receiving ritlecitinib
compared to those receiving placebo. The TEAEs reported in more than 5% (1 in 20) 
participants with RA receiving rit lecitinib were influenza and ly mphopenia. The majority  of 
the AEs were mild in severity. There was 1 mild case of herpes simplex in the ritlecitinib
group that was considered to be treatment -related with no cases in the placebo group. There 
were no clinically relevant changes in vital signs, ECG, or audiometric assessments. By  [CONTACT_269275] 8 time point (as early  as 2 weeks), in the ritlecitinib group, the re were decreases in the 
median platelet counts (25% change from baseline), ly mphocy te counts (21% change from 
baseline), neutrophil counts (24% change from baseline), and hemoglobin (3% change from 
baseline). None of these were deemed to be clinically  relevant b y the investigator and values 
returned to near baseline by  [CONTACT_941] 12 -week follow -up visit.
[IP_ADDRESS].3. Phase 2a Study in Alopecia Areata
Study  B7931005 is a Phase 2a, double -blind, placebo -controlled, multicenter study  to 
evaluate the efficacy  and safet y profile o f ritlecitinib and PF- 06700841 (a TYK2/JAK1 
inhibitor) in participants with moderate to severe AA. The stud y consists of the initial 

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 1924-week double -blind treatment period, an up to 12 - month single- blind extension period, and 
a 6-month crossover open- label extension period. A total of 142 participants were 
randomized to study  treatment; 47 participants received placebo, 48 participants received 
ritlecitinib, and 47 participants received PF -06700841.
During the initial 24 -week double -blind treatment period, participants in the ritlecitinib group 
were treated with 200 mg of ritlecitinib QD during a 4 -week induction phase, followed by  
[CONTACT_156229] 50 mg QD in a maintenance phase. At Week 24, an interim analy sis provided 
data on both efficacy  and safet y and indica ted clinical improvement for participants treated 
with ritlecitinib.
During the initial 24 -week treatment period of Study  B7931005, there were no deaths and no 
participants in the ritlecitinib treatment group experienced an SAE. The proportion of 
participa nts who experienced TEAEs in the placebo treatment group (74.5%) was 
comparable with the ritlecitinib treatment group (62.5%). The TEAEs reported in more than 
5% (1 in 20) participants with AA receiving ritlecitinib were headache, infections of upper 
respi [INVESTIGATOR_53121], acne, diarrhea, nausea, and skin infections. The majorit y of events were 
mild. No serious infections, malignancies, cases of herpes zoster, or cases of herpes simplex 
were reported in the ritlecitinib group. Hematological changes were observe d in both active 
groups during the induction and maintenance periods, but were not associated with clinically  
relevant TEAEs. During the induction period, when participants received ritlecitinib 200 mg 
QD for 4 weeks, decreases in mean platelet and l ymphoc yte counts ( -18% and - 24% mean 
change from baseline, respectivel y) were observed in the ritlecitinib group. During the 
maintenance period, when participants received 50 mg QD for 20 weeks, there was 
improvement in the platelet and ly mphocy te counts in the ritlecitinib group. Neutrophil 
counts were increased at Week 4 (12% change from baseline) and Week 24 (10% change 
from baseline) in the ritlecitinib treatment group. Two participants in the ritlecitinib group 
discontinued due to TEAEs. 
In addition to the initial 24 -week period, the trial included 2 extensions. Extension 1 was a 
Single -Blind Extension Period in which the participants had treatment withdrawn and were 
then re -treated for up to 24 weeks with the initially  assigned I P after the participants rea ched 
a pre -specified retreatment criterion (ie, 30% hair loss from the regrown hair at Week 24). 
The second extension was a Cross- Over Open Label Extension Period in which the Week 24 
non-responders were assigned the opposite active treatment than the one received in the 
initial (Week 0
-24) treatment period. There were no S[LOCATION_003]RS, serious infections, adverse 
events of QTcF prolongation, malignancies and/or no case of herpes zoster during the 
extension periods.
More detailed information about ritlecitinib can be found in the current version of the 
ritlecitinib IB, which is the SRSD for this study .

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 202.3.Benefit/Risk Assessment
More detailed information about the known and expected benefits and risks and reasonabl y 
expected adverse events of ritlecitinib may be found in the current IB , which is the SRSD for 
this study .
The SRSD for 
tolbutamide istheUSPI  [INVESTIGATOR_874374]4.The main potential side effect of 
tolbutamide is hy poglycemia. Treatment of subjects with 6 -phosphate deh ydrogenase 
(G6PD) deficiency  can result in hemoly tic anemia. Mild adverse reactions include gastro -
intestinal effects (nausea, epi[INVESTIGATOR_874375], heartburn). AEs due to dermatologic, 
hematologic, metabolic and endocrine reactions can occur as described in the USPI .

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template (01 March 2021)
Page 212.3.1. Risk Assessment
Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
Study Intervention :Ritlecitinib
Reductions in platelet counts and 
lymphocyte counts .In B7931005 study, reductions in platelet counts and lymphocyte counts 
were observed during treatment with [ADDRESS_1221060] been selected to 
ensure that only appropriate 
participants are included in the study .
Potential risk of infections. Ritlecitinib is an immunomodulator and, as such, can be associated w ith 
the potential risk of infections (including serious infections), 
opportunistic infections, and viral reactivation.Participants with significant infection 
history will be excluded (See 
Section 5.2) and t he occurrence of 
infection swill be monitored in th e
study.
Potential fetal risk. In animals, ritlecitinib was associated w ith fetal changes in bones and 
some internal organs, and lower fetal body weights.  WOCBP who are unwilling or unable 
to use contraception as defined in the 
study protocol w ill be excluded (See 
Section 5.3.4 . and Appendix 4 ).
Potential risk of secreting into human
milk.It is not known whether ritlecitinib is secreted into human milk. Ritlecitinib should not be administered 
to breastfeeding w omenand exposure 
during breastfeeding should be 
reported to [COMPANY_007] Safety (See 
Section [IP_ADDRESS] ).
Study Intervention :Tolbutamide
Phototox icity Porphyria cutanea tarda and photosensitivity reactions have been 
reported w ith sulfonylureas.5The risk of phototoxicity with a single 
dose of tolbutamide (500 mg) is 
considered to be low. Additionally, 
participants will remain at the clinic 
during study participation and will be 
monitored .

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template (01 March 2021)
Page 22Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
Hypoglycemia Tolbutamide is an oral blood glucose lowering drug of the sulfonylurea 
category. As with all sulfonylurea medications ,there is a potential risk 
of hypoglycemia in patients with renal/hepatic/adrenal/pi[INVESTIGATOR_12978]. Elderly, debilitated, malnourished patients or those taking 
beta-adrenergic blocking drugs may be at increased risk of 
hypoglycemic epi[INVESTIGATOR_1841]. Severe/ prolonged exercise and alcohol use may 
also increase the risk of hypoglycemia.The risk of clinically significant 
hypoglycemia with a single dose of 
tolbutamide (500 mg) is considered to 
be low . In addition, the study will 
enroll healthy volunteers and exclude 
subjects with metabolic conditions that 
would increase their risk of 
participation. Subjects w ill remain at
the clinic during study participation ; 
physical activity, nutrition, and 
laboratory results will be monitored.
Gastrointestinal, derm atological, 
hematological, metabolic, and 
endocrine reactions .Potential adverse reactions associated w ith tolbutamide or sul fonylurea 
treatment.5A single dose of tolbutamide (500 mg) 
will be administered as part of the 
B7981069 and the risk of associated 
adverse reactions or laboratory 
abnormalities is low. Laboratory 
results and signs/symptoms will be 
monitored.

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 232.3.2. Benefit Assessment
Neither ritlecitinib nor tolbutamide is expected to provide an y clinical benefit to healthy 
participants. This study  is designed primaril y to generate PK, safet y, and tolerability data for 
further clinic al development of ritlecitinib .
2.3.3. Overall Benefit /Risk Conclusion
Taking into account the measures to minimize risk to study  participants, the potential risks 
identified in association with ritlecitinib and tolbutamide are justified by [CONTACT_874385], vitiligo, RA, UCand CD treated with 
ritlecitinib .
3.OBJECTIVES AND ENDPO INTS
Objectives Endpoints
Prim ary: Prim ary: 
 To evaluate the effect of multiple -dose ritlecitinib 
(PF-06651600) on the PKof a single, oral dose of 
tolbuta mide in healthy participants . Cmaxand AUC inf(if data permit, otherwise AUC last) of 
tolbutamide .
Secondary : Secondary : 
 To evaluate the safety and tolerability of ritlecitinib 
when coadministered with a single dose of 
tolbutamide. Incidence of treatment -emergent adverse events
Other/Exploratory: Other/Exploratory: 
 To characterize the PK of a single oral dose of 
tolbutamide in healthy participants.Plasma tolbutamide PK parameters:T max, AUC last,
CL/F , V z/Fand t ½, as data permit .
4.STUDY DESIGN
4.1.Overall Design
This is a P hase 1, 2-period , multiple -dose, open -label , single fixed sequence study of the 
effect of 
ritlecitinib on tolbutamide pharmacokinetics in healthy participants. A total of 
approximately  12health ymale and/or female participants will be enrolled in the study  to 
obtain at least [ADDRESS_1221061] dose of study  medication. 
Participants will report to the CRU the day  prior to Day 1 dosing (Day  
-1) in Period 1 for 
both treatment sequences. Participants will remain in the CRU for a total of 16 days and 
15nights. This includes 4days and 4 nights (starting the night of admission to the CRU) in 
Period 1and 1 2days and 1 1nights in Period 2. There will be no washout period between
2treatment periods.

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 24In Period 1, participants will be dosed with a single administration of tolbutamide 500mg 
tablet on Day 1. Tolbutamide PK will be assessed for 36hours following dosing. Period 1 
will be immediately  followed by  [CONTACT_29621] 2 with no washout. In Period 2, participants will be 
dosed with oral200 mg ritlecitinib QD for 10days followed by  [CONTACT_17814] a single 
dose of 500mg tolbutamide oral tablet within approximately 5 minutes after administration 
of a 200
-mg dose of ritlecitinib on the morning of Day  10. Tolbutamide PK in Period 2 will
again be assessed at pre -dose and over 
36hours after tolbutamide dosing. (Table 3)
Table 3. Treatment Flow Diagram
Period Day*Treatm ent
1 1 Tolbutamide 500mg (single dose)
2 1-9 Ritlecitinib 200mg QD
10 Ritlecitinib 200mg QD + tolbutamide 500mg (single dose)
11 No treatment given 
12 No treatment given (discharge)
Follow -up 28-35after last dose of 
investigational productFollow -upphone contact 
*Note: Day is relative to the first day of study intervention dosing (including tolbutamide and ritlecitinib )in 
each period.
Participants will have a telephone contact [CONTACT_2669] [ADDRESS_1221062] given the short 
time between the 2periods .This is an open -label study  not requiring an assessment of 
efficacy  or pharmacody namics markers ,but it will include PK estimati on for DDIs.
Since tolbutamide has a t ½of 4.5 – 6.[ADDRESS_1221063] 1 female participant.
4.2.2. Collection of Retained Research Samples
Retained Research Samples will be collected and stored for further anal yses which may , for 
example, provide greater understanding of the study  intervention .

Ritlecitinib ( PF-06651600 )
Protocol B798106 [ADDRESS_1221064] ritlecitinib dose currently  being evaluated in Phase 3 study  for 
AA program. The dose level of 2 00mg QD has demonstrated its safet y and tolerability for 
upto 14 days in healthy  participants (B7981001), up to 4 weeks in participants with AA
(B7931005) and up to 8weeks in RA participants (B7981006) ( Refer to Section 2.2.4).
Enzy me induction can take several day s for effects tomanifest and alter enzy me activity . 
M
ultiple dose administration of the investigational drug for a minimum of [ADDRESS_1221065] completed the study  if he/she has completed all periods of 
the study  including the last scheduled procedure shown in the SoA.
5.STUDY POPULATION
This study  can fulfill its objectives only  if appropriate participant s are enrolled. The 
following eligibility  criteria are designed to select participant s for whom participation in the 
study  is considered appropriate. All relevant medical and nonmedical c onditions should be 
taken into consideration when deciding whether a particular participant is suitable for this 
protocol .
Prospective approval of protocol deviations to recruitment and enrollment criteria ,also 
known as protocol waivers or exemptions, isnot permitted
.

Ritlecitinib ( PF-06651600 )
Protocol B798106 [ADDRESS_1221066] y:
Age and Sex :
1.Male and female p articipant smust be 18 to 65years of age, inclusive ,at the time of 
signing the ICD.
Refer to Appendix 4forreproductive criteria for male (Section 10.4.1 )and female
(Section 10.4.2) participant s.
Type of Participant and Disease Characteristics:
2.
Male and/or female participants who are health y as determined b y medical evaluation 
including medical history, full phy sical ex amination ( includ ingBPand pulse rate 
measurement s), clinical laboratory  tests, and [ADDRESS_1221067] y with all scheduled visits, treatment 
plan, laboratory  tests, lifesty le considerations, and other study  procedu res.
Weight:
4.BMI of 17.5 to 30 .5kg/m2; and a total body  weight >50 kg (110 lb).
Informed Consent:
5. Capable of giving signed informed consent as described in Appendix 1 ,which 
includes compliance with the requirements and restrictions listed in the I CDand in 
this protocol.
5.2. Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions:
1.Evidence or history  of clinica lly significant hematological, renal, endocrine, 
pulmonary , gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic al, 
dermatological or allergic disease (including drug allergies, but excluding untreated, 
asymptomatic, seasonal allergies at the time of dosing ).
2.Any condition possibly  affecting drug absorption (eg, gastrectomy , cholecy stectom y).
3.Known immunodeficiency  disorder, including positive serology  for HIVat screening, 
or a first degree relative with a hereditary  immunodeficiency .

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 274.Infection with hepatitis B or hepatitis C viruses according to protocol specific testing 
algorithm.
a.For hepatitis B, all participants will undergo testing for HBsAg and HBcAb . Only  
participants who are both HBsAg negative and HBcAb negative are eligible
(regar dless of the HBsAb result , if the latter is also reported due to local standard 
of care) .
b.For hepatitis C, all participants will undergo testing for HCVAb . Onl y 
participants who are HCVAb negative are eligible .
5.Participants with any  of the following acute or chronic infections or infection history :
Any infection requiring treatment within 2 w eeks prior to the dosing visit.
Any infection requiring hospi[INVESTIGATOR_874376] y within 
60days of the first dose of investigational product .
Any infection judged to be an opportunistic infection or clinically  significant by  
[CONTACT_818319] [ADDRESS_1221068] .
Known active or history  of recurrent bacterial, viral, fungal, my cobacterial or 
other infections.
History  of recurrent (more than one epi[INVESTIGATOR_44715]) localized dermatomal herpes 
zoster, or history  of disseminated (single epi[INVESTIGATOR_1865]) herpes simplex or disseminated 
herpes zoster.
6.History  of febrile illness within [ADDRESS_1221069] label fo r tolbutamide , would be at 
increased safe ty risk if dosed with tolbutamide .
10.History  of hypersensi tivity  to tolbutamide or an y of its excipi[INVESTIGATOR_840].

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 2811.Other medical or psy chiatric condition (including recent [within the past y ear]or 
active suicidal ideation /behavior ,laboratory  abnormality ,or other co nditions or 
situations related to COVID -19 pandemic [ eg, contact [CONTACT_874386], residence, 
or travel to an area with high incidence] )that may  increase the risk ofstudy  
participation or , in the investigator’s judgment, make the participant inappropriate for 
entry  into this study .
12.Known glucose 6
-phosphate dehy drogenase (G6PD) deficiency .
Prior/Concomitant Therapy:
13.Use of prescription or nonprescription drugs and dietary supplements within 7 days or 
5half-lives (whichever is longer) prior to Day  1. Limited use of nonprescription 
medications that are not thought to affect participant safet y or the overall results of 
the study  may  be permitted on a case by  [CONTACT_238129].
Herbal supplement s, hormonal contracepti ves and HRTmust be discontinued at least 
28days prior to the first dose of 
investigational product ; Depo -Proveraand 
SAYANA PRESS must be discontinued at least [ADDRESS_1221070].
14.Systemic therapy  with any  of the medications that are moderate or strong CYP2C9 
inhibitors within 28 days or 5 half -lives (whichever is longer) or moderate or strong 
CYP2C9 inducers within 28 days or 5 half -lives (whichever is longer) prior to the 
first dose of investigational product ( Section 6.8).
15. Vaccination with a live attenuated v accine within [ADDRESS_1221071] dose of 
study  intervention (refer to Section 5.3.5 for additional details) . 
Prior/Concurrent Clinical Study Experience:
16.Previous administration of investigational products (eg, drugs or vaccines) within 
30days (or as determined by  [CONTACT_19970]) or [ADDRESS_1221072] used in this study  (whichever is longer).
17.Known participation in a clinical trial of ritlecitinib and the participant experienced a 
ritlecitinib -
related AE that led to discontinuation or had a ritlecitinib-related SAE.
Diagnostic Assessments:
18.A positive urine drug test.
19.A positive pregnancy  test.
20.BP 140mmHg (s ystolic) or 90mmHg (diastolic), following at least [ADDRESS_1221073]. If BP is  140mmHg (s ystolic) or 90mmHg (diastolic), the BP should 

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 29be repeated 2 more times and the average of the 3 BP values should be used to 
determine the participant ’s eligibility .
21.Any of the following conditions:
Screening 12- lead ECG that demonstrates:
Clinically  significant abnormalities requiring treatment (eg, acute my ocardial 
infarction, serious tach y-or brad y-arrhythmias) or indicating serious 
underly ing heart disease (eg, cardiomy opathy , Wolff Parkinson –White 
syndrome);
Confirmed QTcF ( time from the start of the Q wave to the end of the T wave 
on ECG corrected using Fridericia’s correction factor) prolongati on 
(>450 milliseconds).
Long QTSyndrome, a family  history  of Long QT Sy ndrome, or a history  of 
Torsades de Pointes;
22.Participant s with 
ANY of the following abnormalities in clinical laboratory  tests at 
screening, as assessed b y the study -specific laborator y and confirmed b y a single 
repeat test, if deemed necessary :
AST or ALT level >1.5 × ULN ;
Total bilirubin level > 1.5 × ULN;
Hemoglobin level 120 g/L (12.0 g/dL);
Platelet count 150 × 109/L (150,000 cells/mm3) ;
WBC count of  3.0 × 109/L (3000 cells/mm3);
ANC 1500 cells/mm3;
ALC800 cells/mm3;
eGFR 60 mL /min/1.73 m2based on the CKD -EPI[INVESTIGATOR_10908];
In the opi[INVESTIGATOR_22747] (or designee), have an y clinically 
significant laboratory  abnormality  that could affect interpretation of stud y data or 
the participan t's participation in the study .

Ritlecitinib ( PF-06651600 )
Protocol B798106 [ADDRESS_1221074] evidence of untreated or inadequatel y treated active or latent infection with 
Mycobacterium tuberculosis (TB)as follow s(see details in Appendix 2 ).
A posi tive QFT -GIn-Tube test performed within the [ADDRESS_1221075] onl y with approval from the [COMPANY_007] 
Medical Monitor on a case by  [CONTACT_413] .
Note: If a participant has previously  received an adequate course of therapy  for 
either latent (9 months of isoniazid in a locale where rates of primary  multi drug 
resistant TB infection are <5% or an acceptable alternative regimen) or active 
(acceptable multi drug regimen) TB infection, neither a QFT -GIn-Tube test nor a 
[COMPANY_003] test need be obtained.
A participant who is being treated for latent or active TB infection is not eligible 
for this study .
Other Exclusions:
24.History  of alcohol abuse or binge drinking and/or any  other illicit drug use or 
dependence within 6 months of Screening. Binge drinki ng is defined as a pattern of 
5(male s)and 4 (female s) or more alcoholic drinks in about 2 hours. As a general 
rule, alcohol intake should not exceed 14 units per week (1 unit= 8ounces [240 mL] 
beer, 1 ounce [30 mL] of 40% spi[INVESTIGATOR_107060] 3 ounces [90 mL] of wine).
25. Use of tobacco/nicotine containing products in excess of 5 cigaret tes/day .
26.History  of severe allergic or anaphy lactic reaction to kinase inhibitors orexcipi[INVESTIGATOR_840] (if 
known, document the specific excipi[INVESTIGATOR_874377] ).
27.Blood donation (excluding plasma donations) of approximately  1pi[INVESTIGATOR_11731] (500 mL)or 
more within 60days prior to dosing .
28.Unwilling or unable to comply  with the criteria in the Lifesty le Considerations
section of this protocol.
29.Investigator site staff or [COMPANY_007] employ ees directl y involved in the conduct of the 
study , site staff otherwise supervised by  [CONTACT_093], and their respective family  
members .  

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 315.3.Lifestyle Considerations
The following guidelines are provided:
5.3.1. Meals and Dietary Restrictions
Participants must abstain from all food and drink (except water) at least 12hours 
prior to an y safety laboratory evaluations.
Noncaffeinated drinks (except grapefruit or grapefruit -related citrus fruit juices , see
below) may  be consumed with meals and the evening snack.
OnPK day s (Period 1 Day 1 and Period 2 Day 10), participants should begin 
breakfast approximately  [ADDRESS_1221076] on other study  
days provided other restrictions are followed.
OnPK day s (Period 1 Day 1 and Period 2 Day 10), lunch will be provided 
approximately  4hours after tolbutamide dosing. Food restrictions only  apply  on the 
days when tolbutamide is dosed.
OnPK day s (Period 1 Day 1and Period 2 Day 10), d inner will be provided 
approximately  9to [ADDRESS_1221077] y on 
the day s when tolbutamide is dosed.
An evening snack ispermitted.
Participants will refrain from consuming red wine, grape
fruit, or grapefruit- related 
citrus fruits (eg, Seville oranges, pomelos, fruit juices) from [ADDRESS_1221078] until collection of the final PK blood sample.
While participants are confined, their total daily  nutritional composition should be 
approximately  55% carbohy drate, 30% fat, and 15% protein. The dail y caloric intake 
per participant should not exceed approximately  3200 kcal.
5.3.2. Caffeine, Alcohol, and Tobacco
Participants will abstain from alcohol for 24 hours prio r (or as specified above for red 
wine) to admission to the CRU and during confinement in the CRU. Participan ts may  
undergo an alcohol breath test or blood alcohol test at the discretion of the 
investigator.
Participan ts will abstain from caffeine containing products for 24 hours prior to the 
start of dosing and during confinement in the CRU.

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 32Participan ts will abstain from the use of tobacco or nicotine containing products for 
24 hours prior to dosing and during confinement in the CRU .
5.3.3. Activity
Participants will abstain from strenuous exercise (eg, heav y lifting, weight training, 
calisthenics, aerobics) for at least 48 hours prior to each blood collection for clinical 
laboratory  tests. Walking at a normal pace will be permitted;
In order to stand ardize the conditions on PKsampling day s, participant s will be 
required to refrain from ly ing down (except when required for BP, pulse rate , and 
ECG measurements), eating, and drinking beverages other than water during the first 
[ADDRESS_1221079] of contraception methods (see Appendix 4 Section 10.4) 
and will confirm that the participant has been instructed in its consistent and correct use. At 
time points indicated in the S
oA, the investigator or designee will inform the participant of 
the need to use highl y effective contraception consistently  and correctly  and document the 
conversation and the participant ’s affirmation in the participant ’s chart ( participants need to 
affirm their consistent and correct use of at least 1 of the selected methods of contraception)
considering that their risk for pregnancy  may  have changed since the last visit . In addition, 
the investigator or designee will instruct the pa rticipant to call immediately  if the selected 
contraception method is discontinued or if pregnancy  is known or suspected in the participant
or partner.
5.3.5. Vaccination 
Vaccination with a live attenuated v accine is prohibited within the [ADDRESS_1221080] been 
vaccinated with live attenuated vaccine sshould be avoided during treat ment and for 6 weeks 
following completion of treatment. Following vaccination with live component vaccines, the 
virus may  be shed in bodily  fluids, including stool, and there is a potential risk that the virus 
may be transmitted.
Such live attenuated vacci nes include but are not limited to: FluMist®(intranasal influenza 
vaccine), attenuated rotavirus vaccine, varicella (chickenpox) vaccine, attenuated ty phoid 
fever vaccine, oral polio vaccine, MMR vaccine, vaccinia (smallpox) vaccine, and Zostavax®
(zoster vaccine live).
Vaccines (including COVID -19 vaccines) that are not live attenuated are permitted.

Ritlecitinib ( PF-06651600 )
Protocol B798106 [ADDRESS_1221081]/entered in the study . 
Screen failure data are collected and remain as source and are not reported on the CRF .
Individuals who do not meet the criteria for participation in this study  (screen failure) may  be 
rescreened .
6.
STUDY INTERVENTION
Study  intervention is defined as any  investigational intervention(s), marketed product(s), 
placebo, medical device(s) , or study  procedure(s) intended to be administered to a study  
participant according to the study  protocol.
For the purposes of this protocol, the term investigational product may  be used 
synony mously  with study  intervention .
6.1.Study Intervention(s) Administered
For this study , the investigational products are ritlecitinib (PF-06651600, 200 mg provided as 
four 50mg capsule s) and tolbutamide ( 500 mg provided as one 500 mg tablet).
Ritlecitinib ( PF-06651600) [ADDRESS_1221082] (ritlecitinib [ PF-06651600 ]and/or tolbutamide ) 
will be carried out according to the conditions described in the SoA andSection 5.3.[ADDRESS_1221083] , participants will 
receiv e tolbutamide at approximately  08:00 hours (± 3 hours) with approximately  [ADDRESS_1221084] , ritlecitinib and 
tolbutamide doses will be administered at 08:00 hours (±2 hours), with ambient temper ature 
water to a total volume of approximately  [ADDRESS_1221085]. 
After swallowing the ritlecitinib dose, tolbutamide should be administered within 
approximately  5minutes. 
For coadministration day, participants may  receive a dditional ambient temperature water up 
to 100 mL, if needed .
The time of ritlecitinib and tolbutamide administration swill be recorded.

Ritlecitinib ( PF-06651600 )
Protocol B798106 [ADDRESS_1221086] prior to swallowing.
In order to standardize the conditions on PK sampling day s, all participants will be required 
to refrain from ly ing down (except when required for BP, pulse rate , and ECG 
measurements), eating, and drinking beverages other than water during the first 4 hours after 
dosing .
6.2.Preparation/Handling/Storage/Accountability
1.
The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study  intervention sreceived and an y 
discrepancies a re reported and resolved before use of the study  intervention.
2.Only  participants enrolled in the study  may  receive study  intervention and only  
authorized site staff may  supply  or administer study  intervention. All study  
interventions must be stored in a se cure, environmentally  controlled, and monitored 
(manual or automated recording) area in accordance with the labeled storage 
conditions with access limited to the investigator and authorized site staff. At a 
minimum, daily  minimum and maximum temperatures f or all site storage locations 
must be documen ted and available upon request. Data for nonworking day s must 
indicate the minimum and maximum temperature ssince previousl y documented for 
all site storage locations upon return to business.
3.Any excursions from the study  intervention label storage conditions should be 
reported to [COMPANY_007] upon discovery  along with an y actions taken. The site should 
activel y pursue options for returning the stud y intervention to the storage conditions 
described in the labeling, as soon as possible. Once an excursion is identified, the 
study  intervention must be quarantined and not used until [COMPANY_007] provides permission 
to use the study  intervention. Specific details regarding the definition of an excursion 
and information the site should report for each excursion will be provided to the site 
in the PCRU site procedures.
4.Any storage conditions stated in the SRSD will be superseded by  [CONTACT_177264].
5.Study  interventions should be stored in their ori ginal containers and in accordance 
with documentation provided to the site.
6.The investigator, institution, or the head of the medical institution (where applicable) 
is responsible for stud y intervention accountability, reconciliation, and record 
maintenanc e (ie, receipt, reconciliation, and final disposition records) , such as the 
IPAL or sponsor -approved equivalent. All study  intervention s will be accounted for 
using a study  intervention accountabilit y form/record.
7.Further guidance and information for the f inal disposition of unused study  
interventions are provided by  [CONTACT_874387], All destruction must be 

Ritlecitinib ( PF-06651600 )
Protocol B798106 [ADDRESS_1221087] complaint, notify the sponsor within 1 business day  of 
discovery .
6.2.1. Preparation and Dispensing
Within this protocol, preparation refers to the investigator site activities performed to make 
the study  intervention ready  for administration or dispensing to the participant by [CONTACT_216479]. Dispensing is defined as the provision of study intervention , concomitant treatments, 
and accompan ying information by  [CONTACT_22806](s) to a healthcare provider, 
participant in accordance with this protocol. L ocal health authority  regulations or investigator 
site guidelines may  use alternati ve terms for these activities. 
Ritlecitinib (200 mg, four 50 mg capsules )and tolbutamide ( 500 mg , provided as one 500 mg 
tablet )
will be prepared at the CRU in the individual dosing containers by  2operators, 1of 
whom is an appropriatel y qualified and experienced member of the stud y staff (eg, ph ysician, 
nurse, ph ysician’s assistant, nurse practitioner, pharmacy  assistant/technician, or pharmacist). 
The tablets and capsules will be provided in unit dose containers and labe led in accordance 
with [COMPANY_007] regulations and the clinical site’s labeling requirements. 
6.3.Measures to Minimize Bias: Randomization and Blinding
6.3.1. Allocation to Study I ntervention
The investigator’s knowledge of the treatment should not influence the decision to enroll a 
particular participant or affect the order in which participants are enrolled.
The investigator will assign participant numbers to the participants as they  are screened for 
the study . [COMPANY_007] will provide a randomizati on schedule to the investi gator site 
and, in 
accordance with the randomization numbers, the participant will receive the study  treatment 
regimen assigned to the corresponding randomization number.
6.4. Study Intervention Compliance
Participants will receive study  intervention directly  from the investigator or designee, under 
medical supervision. The date and time of each dose administered in the clinic will be 
recorded in the source documents and recorded in the CRF . The dose of study interventio n 
and study  participant identification will be confirmed at the time of dosing by  a member of 
the study  site staff. The oral cavit y of each participant will be examined following dosing to 
ensure the investigational product was taken.
6.5.Dose Modification 
Dose modification is not allowed in the current study .

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 366.6.Continued Access to Study Intervention After the End of the Study
No intervention will be provided to study  participants at the end of their study participation .
6.7.Treatment of Overdose
For this study , any dose of ritlecitinib greater than 800 mgwithin a 24- hour time period will 
be considered an overdose.
Any dose of 
tolbutamide greater than 3000 mgwithin a 24-hour time period will be 
considered an overdose.
There is no specific antidote or specific tre atment for an overdose of ritlecitinib . For 
tolbutamide, investigators should consider the treatment of overdose as per USPI .5
In the event of an overdose, the investigator should:
1.Contact [CONTACT_10990] .
2.Closely  monitor the participant for an y AEs/SAEs and laboratory  abnormalities until 
ritlecitinib and tolbutamide can no longer be detected sy stemically  (at least 2 day s).
3.Document the quantit y of the excess dose as well as the duration of the overdose in 
the CRF.
4. Overdose is reportable to [COMPANY_007] Safety  only when associated with an SAE.
5.Obtain a blood sample for PK anal ysis within [ADDRESS_1221088] dose of 
study  intervention if requ ested by  [CONTACT_7195] (determined on a case -by-case 
basis).
Decisions regarding dose interruptions or modifications will be made by  [CONTACT_78256].
6.8.
Concom itant Therapy
Use of prescription or nonprescription drugs and dietary and herbal supplements are 
prohibited within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study  
intervention . Limited use of nonprescription medications that are not believed to affect 
participant safety  or the overall results of the study may  be permitted on a case-by-case basis 
following approval b y the sponsor .Acetaminophen /paracetamol may be used at doses of 
≤3g/day .Ibuprofen may  be used at doses ≤1200 mg/day .
Systemic therapy  with any  of the medications that are moderate or strong CYP2C9 inhibitors 
or moderate or strong CYP2C9 inducers within 28 days or 5 half -lives (whichever is longer) 
are prohibited prior to the first dose of investigational product.

Ritlecitinib ( PF-06651600 )
Protocol B798106 [ADDRESS_1221089] dose of study  
treatment and remain off hormonal therap y for the duration of the study . Depo -Provera
must be discontinued at least [ADDRESS_1221090] then be used ( Section 10.4.3 ).
All concomitant treatments taken during the study  must be recorded with indication, daily  
dose, and start and stop dates of administration. Concomitant drug and non -drug treatment 
will be collected. All participants will be questioned about concomitant tre atment at each 
clinic visit.
Treatments taken within [ADDRESS_1221091] will be documented as concomitant treatments.
6.8.1. Rescue Medic ine
There is no specific rescue therap y to reverse the AEs caused b yritlecitinib or tolbutamide ; 
standard medical supportive care must be provided to manage the AEs. 
7.DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
DISCONTIN UATION/WITHDRAWAL
7.1.Discontinuation of Study Intervention
It may  be necessary  for a participant to permanently  discontinue study  intervention .Reasons 
for permanent discontinuation of study intervention include the following as outlined in 
Section 10.8.2.
If study  intervention is definitively  discontinued, the participant will not remain in the study  
for further evalu ation. See the SoA for data to be collected at the time of discontinuation of 
study  intervention.
See Appendix 8 for guidelines for safet y monitoring and discontinuation guidelines.
7.2.Participant Discontinuation/ Withdrawal
From the Study
A participant may withdraw from the stud y at an y time at his/her own request. Reasons for 
discontinuation from the study  include the following:
Refused further follow -up;
Lost to follow -up;
Death ;
Study  terminated by  [CONTACT_3211] ;

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 38At the discretion of the investigator for behavioral, compliance, or administrative 
reasons.  
At the time of discontinuing from the stud y, if possible, an earl y discontinuation visit should 
be conducted. See the SoA for assessments to be collected at the time of study  
discontinuation and follow -up and for an y further evaluations that need to be completed. 
The early  discontinuation visit applies only  to participants who are enrolled/ randomized and 
then are prematurely  withdrawn from the study .Participants should be questioned regarding 
t
heir reason for withdrawal.  
The participant will be permanentl y discontinued both from the study intervention and from 
the study  at that time.
If a participant withdraws from the study , he/she may  request destruction of any  remaining 
samples taken and no
t tested ,and t he investigator must document any  such requests in the 
site study  records and notify  the sponsor accordingly .
If the participant withdraws from the study  and also withdraws consent (see Section 7.2.1 for 
disclosure of future information, no further evaluations should be performed and no 
additional data should be collected. The sponsor may  retain and continue to use any  data 
collected befor e such withdrawal of consent.
Lack of completion of all or an y of the withdrawal/earl y termination procedures will not be 
viewed as protocol deviations so long as the participant ’s safet y was preserved.
7.2.1. Withdrawal of Consent 
Participant s who request to di scontinue receipt of study  intervention will remain in the study  
and must continue to be followed for protocol -specified follow -
up procedures. The onl y 
exception to this is when a participant specificall y withdraws consent for any further contact 
[CONTACT_874388]. Participant s should notify  the investigator in writing of the decision to withdraw 
consent from future follow -up, whenever possible. The withdrawal of consent should be
explained in detail in the medical records b y the investigator, as to whether the withdrawal is 
only from further receipt of study  intervention or also from study  procedures and/or 
posttreatment study  follow -up, and entered on the appropriate CRF page. In the event that 
vital status (whether the participant is alive or dead) is being measured, publicly  available 
information should be used to determine vital status only  as appropriatel y directed in 
accordance with local law.
7.3.Lost to Fol low-up 
A participant will be considered lost to follow -up if he or she repeatedl y fails to return for 
scheduled visits and is unable to be contact[INVESTIGATOR_530] b y the study  site.

Ritlecitinib ( PF-06651600 )
Protocol B798106 [ADDRESS_1221092] be taken if a participant fails to return to the clinic for a required 
study  visit:
The site must attempt to contact [CONTACT_288949]/or 
should continue in the study ;
Before a parti cipant is deemed lost to follow -up, the investigator or designee must 
make every  effort to regain contact [CONTACT_6635] (where possible, 3 telephone 
calls and, if necessary , a certified letter to the partic ipant’s last known mailing 
address or local equivalent methods). These contact [CONTACT_14316]’s medical record ;
Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study.
8.STUDY ASSESSMENTS AND PROCEDURES
The investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing an y stud y-specific procedures.
Study  procedures and their timing are summarized in the SoA.Protocol waivers or 
exemptions are not allowed.
Safety  issues should be discussed with the sponsor immediately  upon occurrence or 
awareness to determine whether the participant should continue or discontinue study  
intervention.
Adherence to the stud
y design requirements, including those specified in the SoA, is essential 
and required for stud y conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility  or record reasons for 
screening failure, as applicable.
Participant s will be screened within 28 days prior to administration of the study  intervention
to confirm that they  meet the study  population criteria for the study . If the time between 
screening and dosing exceeds 28 days as a result of unexpected delay s (eg, delay ed drug 
shipment), then participants d o not require rescreening if the laboratory  results obtained prior 
to first dose administration meet eligibility  criteria.
A participant who qualified for this protocol but did not enroll f roman earlier group may be 
used in a subsequent group withoutrescreening ,provided laboratory  results obtained prior to 
the first dose administration meet eligibility  criteria for this study .In addition, other clinical 

Ritlecitinib ( PF-06651600 )
Protocol B798106 [ADDRESS_1221093] be informed of these incidents in a timely  manner.
Ifan IVcatheter is utilized for bl ood sample collections, ECGs and vital sign assessments 
(pulse rate andBP) should be collected prior to the insertion of the catheter .
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact [CONTACT_19987] .
The total blood sampling volume for individual participant s in this study  is approximately  
145mL.The actual collection times of blood sampling may  change. Additional blood 
samples may  be taken for safet y assessments at times specified by [CONTACT_4618], provided the total 
volume taken during the study does not exceed [ADDRESS_1221094] ructed on the information in the 
Lifesty le Considerations andConcomitant Therapy sections of the protocol.
8.1.Efficacy Assessments
Not Applicable.
8.2.Safety Assessments
Planned time points for all safety assessments are provided in the SoA.Unscheduled clinical 
laboratory  measurements may  be obtained at any  time during the stud y to assess any 
perceived safety  issues.
8.2.1. Physical Examinations
A complete physical examination will include , at a minimum, head, ears, eyes, nose, mouth, 
skin, heart and lung examinations, ly mph nodes, and gastrointestinal, musculoskeletal, and 
neurological s ystems. 
A brief physical examination will include, at a minimum, asse ssments of general appearance, 
the respi[INVESTIGATOR_2866] s ystems, gastrointestinal including lymph nodes, skin 
and 
participant reported s ymptoms.

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 41Physical examinations may  be conducted by  a ph ysician, trained ph ysician's assistant, or 
nurse pract itioner as acceptable according to local regulation. 
Height and weight will also be measured and recorded as per the SoA. For measuring weight, 
a scale with appropriate range and resolution is used and must be placed on a stable, fl at 
surface. Participant s must remove shoes, bulky  layers of clothing, and jackets so that only  
light clothing remains. They  must also remove the contents of their pockets and remain still 
during measurement of weight. 
Physical examination findings collected during the study  will be considered source data and 
will not be required to be reported, unless otherwise noted. An y untoward physical 
examination findings that are identified during the active collection period and meet the 
definition of an AE o r SAE ( Appendix 3 ) must be reported according to the processes in 
Sections 8.3.1 to 8.3.3 .
8.2.2. Vital Signs
Supi[INVESTIGATOR_78235]
’s arm supported at the level of the heart, and 
recorded to the nearest mm Hgafter approximately  5minutes of rest . The same arm 
(preferabl y the dominant arm) will be used throughout the study. Participant s should be 
instructed not to speak during measurements.
The same properl y sized and calibrated BP cuff will be used to measure BP each time. The 
use of an automated device for measuring BP and pulse rate is acceptable; however, when 
done manuall y, pulse rate will be measured in the brachial/radial artery  for at least 
30seconds. When the timing of these measurements coincides with a blood collection, BP 
and pulse rate should be obtained prior to the nominal time of the blood collection .
Additional collection times, or changes to collection times, o f BP and pulse rate will be 
permitted, as necessary, to ensure appropriate collection of safety  data.
[IP_ADDRESS]. Temperature
Temperature will be measured orall y.No eating, drinking, or smoking is allowed for 
15minutes prior to the measurement.
8.2.3. Electrocardiograms
Standard 12-l ead E CGs utilizing limb leads (with a 10 second rh ythm strip) should be 
collected at times specified in the SoA section of this protocol using an ECG machine that 
automatically  calculates the heart rate and measures PR, QT, and QTc intervals and QRS 
complex .
Alternative lead placement methodology using torso leads (eg, Mason- Likar) is not 
recommended given the potential risk of discrepancies with ECGs acquired using standard 
limb lead placement. All scheduled ECGs should be performed after the participant has 
rested quietly for at least 10 minutes in a supi[INVESTIGATOR_2547]. 
To ensure safet y of the participant s, a qualified individual at the investigator site will make 
comparisons to baseline measurements (Period 1, Day  1 pre-dose).Additional ECG 

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 42monitoring will occur if a) a postdose QTc Finterval is increased by  ≥60 msecfrom the 
baseline 
andis >450 msec; or b) an absolute QT value is ≥[ADDRESS_1221095] 
hourly  until QTc values from 2 succes sive ECGs fall below the threshold value that triggered 
the repeat measurement.
If a) a postdose QTc Finterval remains ≥60msecfrom the baseline andis >450 msec,or b) 
an absolute QT value is ≥500 msecfor an y scheduled ECG for greater than 4 hours (or 
sooner , at the discretion of the investigator), or c) QTcFintervals get progressively longer, 
the participant should undergo continuous ECG monitoring. A cardiologist should be 
consulted if QTc intervals do not return to less than the criterion listed above after 8 hours of 
monitoring (or sooner ,at the discretion of the investigator).
In some cases, it may  be appropriate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality. It is important that leads beplaced in the 
same positions each time in order to achieve precise ECG recordings. If a m achine -read QTc 
value is prolonged, as defined above, repeat measurements may  not be necessary  if a 
qualified medical provider’s interpretation determines that the QTcF values are in the 
acceptable range.
ECG values of potential clinical concern arelisted inAppendix 7.
8.2.4. Clinical Safety Laboratory Assessments
See Appendix [ADDRESS_1221096] any  
clinically  relevant changes occurring during th e study  in the AE section of the CRF. 
Clinically  significant abnormal laboratory  findings are those which are not associated with 
the underl ying disease, unless judged by  [CONTACT_78259]'s condition.
Alllaboratory  tests with values considered clinically  significantl y abnormal during 
participation in the study  or within [ADDRESS_1221097] dose of study  intervention 
should be repeated until the values return to normal or baseline or are no longer considered 
clinically  significant b y the investigator or medical monitor.
If such values do not return to normal/baseline within a period of time judged reasonable b y 
the investigator, the etiology  should be identified and the sponsor notified.

Ritlecitinib ( PF-06651600 )
Protocol B798106 [ADDRESS_1221098] will be performed after 4 day s 
(i.e. upon completion of 4 x 24 hours in house), or if they  develop COVID- 19 like sy mptoms. 
Additional testing may  be required by  [CONTACT_791783].
8.2.6. Estimated Glomerular Filtration Rate
eGFR will be calculated using the following equation developed b y the CKD -EPI, which 
utilize SCr:
CKD -EPI
If female and SCr is 0.7mg/dL:
GFR (mL/min/1.73 m2) = 144 × (SCr/0.7)–0.329 × 0.993age(× 1.159, if black).
If female and SCr is >0.7 mg/dL:
GFR ( mL/min/1.73 m2) = 144 × (S Cr/0.7) –1.209× 0.993age(× 1.159, if black).
If male and SCr is 
0.9mg/dL:
GFR ( mL/min/1.73 m2) = 141 × (SCr /0.9) –0.411× 0.993age(× 1.159, if black).
If male and SCr is >0.9 mg/dL:
GFR ( mL/min/1.73 m2) = 141 × (S Cr /0.9) –1.209× 0.993age(× 1.159, if black).
8.2.7. Pregnancy Testing
Pregnancy  tests may  be urine or serum tests, but must have a sensitivity of at least 
25mIU/mL. Pregnancy  tests will be performed in WOCBP at the times listed in the SoA . 
Following a negative pregnancy  test result at screening, appropriate contraception must be 
commenced and a second negative pregnancy  test result will be required at the baseline visit 
prior the participant ’sreceiving the study  intervention . Pregnancy  tests will also be done 
whenever 1 menstrual cycle is missed during the active treatment period (or when potential 
pregnancy  is otherwise suspected) and at the end of the study . Pregnancy  tests may  also be 
repeated if requested b y IRBs /ECs or if required by [CONTACT_427].

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 448.3. Adverse Events and Serious Adverse Events , and Other Safety Reporting
The definitions of an AE and an SAE can be fo und in Appendix 3.
AEs may  arise from s ymptoms or other complaints reported to the investigator by  [CONTACT_2416] (or, when appropriate, b y a caregiver, surrogate, or the participant's legall y 
authorized representat ive), or they  may  arise from clinical findings of the Investigator or 
other healthcare providers (clinical signs, test results, etc.).
The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet t
he definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether the 
event meets the criteria for classification as an SAE or caused the participant to discontinue 
thestudy  intervention (see Section 7.1). 
During the active collection period as described in
Section 8.3.1, e ach participant will be 
questioned about the occurrence of AEs in a nonleading manner.
In addition, the investigator may  be requested by  [CONTACT_19989] y to obtain specific follow -
up 
information in an expedited fashion.
8.3.1. Time Period and Frequency for C ollecting AE and SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins from the time the participant provides informed consent, 
which is obtained before the participant ’s participation in the study  (ie, before undergoing 
any study -related procedure and/or receiving study  intervention ), through and including a 
minimum of [ADDRESS_1221099] be recorded on the CRF and the SAE 
reported using the CTSAE Report Form.
Investigators are not obligated to activel y seek information on AE or SAE after the 
participant has concluded study  participation . However, if the investigator learns of an y SAE, 
including a death, at an y time after a participant has completed the study , and he/she 

Ritlecitinib ( PF-06651600 )
Protocol B798106 [ADDRESS_1221100] SAE Report Form.
[IP_ADDRESS].
Reporting SAEs to [COMPANY_007] Safety
All SAEs occurring in a participant during the active collection p eriod as described in 
Section 8.3.[ADDRESS_1221101] SAE Report Form immediately  upon 
awareness and under no ci rcumstance should this exceed 24
hours, as indicated in 
Appendix 3.The investigator will submit any  updated SAE data to the sponsor within 
24 hours of it being available.
[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during the active collection period,
which begins after obtaining informed consent as described in Section 8.3.[ADDRESS_1221102] on the CRF all directly  observed and all spontaneously  reported 
AEs and SAEs reported by  [CONTACT_2299].
8.3.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality  of AE sand SAE sand the 
procedures for completing and transmitting SAE reports are provided in Appendix 3.
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrences.
8.3.3. Follow -
up of AEs and SAEs
After the initial AE/SAE report, the investigator is required to proactivel y follo w each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and 
obtain adequate information until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to follow- up (as defined in Section 7.3).
In general, follow -
up information will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independent determination of 
possibl e causality . Any information relevant to the event, such as concomitant medications 
and illnesses, must be provided.  In the case of a participant death, a summary of available 
autopsy  findings must be submitted as soon as possible to [COMPANY_007] Safety . 
Furth er information on follow -up procedures is given in Appendix 3.
8.3.4.
Regulatory Reporting Requirements for SAEs
Prompt notification by  [CONTACT_11012] a n SAE is essential so that legal 
obligations and ethical responsibilities towards the safet y of participants and the safet y of a 
study  intervention under clinical investigation are met.

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 46The sponsor has a legal responsibility  to notify  both the local regulat ory authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. The 
sponsor will comply  with country -specific regulatory  requirements relating to safet y 
reporting to the regulatory  authorit y, IRBs/ECs, and investigators.
Investigator safety  reports must be prepared for S[LOCATION_003]R saccording to local regulatory  
requirements and sponsor policy  and forwarded to investigators as necessary .
An investigator who receives S[LOCATION_003]Rs or other specific safet y information (eg, summary  or 
listing of SAEs) from the sponsor will review and then file it along with the SRSD(s) for the 
study and will notify  the IRB/EC, if appropriate according to local requirements.
8.3.5. Environmental Exposure, Exposure During Pregnancy or Breastfeeding, and 
Occupational Exposure
Environmental exposure, occurs when a person not enrolled in the study  as a participant 
receives unplanned direct contact [CONTACT_216480]. Such exposure 
may or may  not lead to the occurrence of an AE or SAE. Persons at risk for environmental 
exposure include healthcare providers, famil y members, and others who may be exposed. An 
environmental exposure may  include exposure during pregnancy , exposure during 
breastfeeding, and occupational exposure.
Any such exposure to the study  intervention under study  are reportable to [COMPANY_007] Safet y 
within 24 hours of investigator awareness.
[IP_ADDRESS]. Exposure During Pregnancy
An EDP occurs if: 
A female participant is found to be pregnant while receiving or after discontinuing 
study intervention.
A female is found to be pregnant while being exposed or having been exposed to 
study  intervention due to environmental exposure. Below are examples of 
environmental EDP :  
A female family  member or healthcare provider reports that she is pregnant after 
having been exposed to the study  intervention by  [CONTACT_19991] .
The investigator must report EDP to [COMPANY_007] Safety within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The initial information submitted 
should include the anticipated date of delivery  (see below for information related to 
termination of pregnancy). 
If EDP occurs in a participant, the investigator must report this information to 
[COMPANY_007] Safety  on the CT SA E Report Form and an EDP Supplemental Form, 

Ritlecitinib ( PF-06651600 )
Protocol B798106 [ADDRESS_1221103] dose.
If EDP occurs in the setting of environmental exp osure, the investigator must 
report information to [COMPANY_007] Safet y using the CT SAE Report Form and EDP 
Supplemental Form. Since the exposure information does not pertain to the 
participant enrolled in the study , the information is not recorded on a CRF; 
however, a cop y of the completed CT SAE Report Form is maintained in the 
investigator site file.
Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome. The investigator will follow th
e pregnancy  until 
completion (or until pregnancy  termination) and notify  [COMPANY_007] Safet y of the outcome as a 
follow -up to the initial EDP S upplemental Form. In the case of a live birth, the structural 
integrit y of the neonate can be assessed at the time of b irth. In the event of a termination, the 
reason(s) for termination should be specified and, if clinically  possible, the structural 
integrit y of the terminated fetus should be assessed by [CONTACT_4692] (unless 
preprocedure test findings are conclu sive for a congenital anomal y and the findings are 
reported).
Abnormal pregnancy  outcomes are considered SAEs. If the outcome of the pregnancy  meets 
the criteria for an SAE (ie, ectopic pregnancy , spontaneous abortion, intrauterine fetal 
demise, neonatal death, or congenital anomal y in a live -born bab y, a terminated fetus, an 
intrauterine fetal demise, or a neonatal death), the investigator should follow the procedures 
for reporting SAEs. Additional information about pregnancy  outcomes that are reported to
[COMPANY_007] Safety  as SAEs follows: 
Spontaneous abortion includ ingmiscarriage and missed abortion;
Neonatal deaths that occur within [ADDRESS_1221104] 
to causality , as SAEs. In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly  related to 
exposure to the study  intervention. 
Additional information regarding the EDP may  be requested by  [CONTACT_456]. Further 
follow -up of birth outcomes will be handled on a case -by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s).In the case of paternal exposure, the 
investigator will provide the participant with the Pregnant Partner Release of Information 
Form to deliver to his par tner. The investigator must document in the source documents that 
the participant was given the Pregnant Partner Release of Information Form to provide to his 
partner.

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Exposure During Breastfeeding
An exposure during breastfeeding occurs if: 
A female participant is found to be breastfeeding while receiving or after 
discontinuing study  intervention .
A female is found to be breastfeeding while being exposed or having been exposed to 
study  intervention (ie, environmental exposure). An example of environme ntal 
exposure during breastfeeding is a female family  member or healthcare provider who 
reports that she is breastfeeding after having been exposed to the study  intervention 
by [CONTACT_19991].  
The investigator must report exposure during brea stfeeding to [COMPANY_007] Safety  within 24 hours 
of the investigator’s awareness, irrespective of whether an SAE has occurred. The 
information must be reported using the CT SAE Report Form. When exposure during 
breastfeeding occurs in the setting of environmenta l exposure, the exposure information does 
not pertain to the participant enrolled in the study , so the information is not recorded on a 
CRF. However, a cop y of the completed CT SAE Report Form is maintained in the 
investigator site file.
An exposure during breastfeeding report is not created when a [COMPANY_007] drug specificall y 
approved for use in breastfeeding women (eg, vitamins) is administered in accord with 
authorized use. However, if the infant experiences an SAE associated with such a drug, the 
SAE is reported together with the exposure during breastfeeding.
[IP_ADDRESS]. Occupational Exposure
The investigator must report occupational exposure to [COMPANY_007] Safet y within 24 hours of the 
investigator’s awareness using the CT SAE Report Form regardless of whether there is an 
associated SAE. Since the information does not pertain to a participant enrolled in the study , 
the information is not recorded on a CRF; however, a cop y of the completed CT SAE Report 
Form is maintained in the investigator site file .
8.3.6. Cardiovascular and Dea th Events (Not applicable)
8.3.7. Disease -Related Events and/or Disease -Related Outcomes Not Qualifying as AEs 
or SAEs (Not applicable)
8.3.8. Adverse Events of Special Interest (Not applicable)
[IP_ADDRESS]. Lack of Efficacy (Not applicable)
This section is not applicable because efficacy  is not expected in the study  population.

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 498.3.9. Medical Device Deficiencies (Not applicable)
8.3.10. Medication Errors
Medication errors may  result from the administration or consumption of the study  
intervention by [CONTACT_19995] , or at the wrong time, or at the wrong dosage strength.
Exposures to the 
study  intervention under stud y may occur in clinical trial settings, such as 
medication errors.
Safety Event Recorded on the CRF Reported on the CT SAE Report 
Form to [COMPANY_007] Safety Within 
24Hours of Awar eness
Medication errors All (regardless of whether 
associated with an AE)Only  if associated with an SAE
Medication errors include:
Medication errors involving participant exposure to the study  intervention ;
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the study participant .
Such medication errors occurring to a stud
y participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified within 24 hours .
Whether or not the medication error is accompanied by  [CONTACT_1149], as determined by  [CONTACT_1275], the medication error is recorded on the medication error page of the CRF and, if 
applicable, an y associated AE(s), serious and nonserious, are recorded on theAE page of the 
CRF. 
Medication errors should be reported to [COMPANY_007] Safety within [ADDRESS_1221105] SAE Report 
Form only when associated with an SAE.
8.4.Pharmacokinetics
Blood samples of approximately  3 mL , to provide a pproximately 1 mL plasma , will be 
collected for measurement of plasma concentrations of tolbutamide as specified in the SoA. 
Instructions for the collection and handling of biological samples will be provided in the 
laboratory  manual or by  [CONTACT_456]. The actual date and time (24 -hour clock time) of each 
sample will be recorded.
The actual times may  change, but the number o f samples will remain the same. All efforts 
will be made to obtain the samples at the exact nominal time relative to dosing. Collection of 

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 50samples up to and including 10 hours after dose administration that are obtained within 
10% of the nominal time (eg, within 6 minutes of a 60 -minute sample) relative to dosing will 
not be captured as a protocol deviation, as long as the exact time of the collection is noted on 
the source document and data collection tool (eg, CRF /DCT ).Collection of samples more 
than 10 hours 
after dose administration that are obtained ≤1hour away  from the nominal 
time relative to dosing will not be captured as a protocol deviation, as long as the exact time 
of the collection is noted on the source document and data collection tool (eg, CRF /DCT ). 
Samples will be used to e stimate the PK of tolbutamide .Samples collected for anal yses of 
tolbutamide concentration may  also be used to evaluate safet y or efficacy aspects related to 
concerns arising during or after the study , for metabolite identification, metabolite assay  for 
tolbutamide and/or ritlecitinib, and/or evaluation of the bioanal ytical method, or for other 
internal exploratory  purposes.
Genetic anal yses will not be performed on these plasma samples .Participant confidentiality  
will be maintained.
Samples collected for measurement of plasma concentrations of tolbutamide will be anal yzed 
using a validated anal ytical method in compliance with 
applicable SOPs.
The PK samples must be processed and shipped as indicated in the instructions provided to 
the investigator site to maintain sample integrity . Any  deviations from the PK sample 
handling procedure (eg, sample collection and processing steps, interim storage or shippi[INVESTIGATOR_15889]), including any actions taken, must be documented and reported to the sponsor.  
On a case -by-case basis, the sponsor may  make a determination as to whether sample 
integrity  has been compromised.
8.5.Genetics
8.5.1. Specified Genetics
A 4-mL blood pharmacogenomic sample for DNA isolation will be collected into plastic 
K2-EDTA tubes, as defined in the SoA. DNA samples will be anal yzed for the purpose of 
assessing the impact of allelic variants of CYP2C9 as variation in this gene may  influence the 
metabolism and PK of tol butamide. Additionally , these samples may  also be used for 
retrospective evaluation of additional genetic variants associated with variat ion in PK, 
biomarker response, or to explore AEs
should these be observed. Samples will be retained for 
a period of up to [ADDRESS_1221106] be processed and shipped as indicated in 
the instructions provided to the investigator site, to maintain sample integrity. An y deviations 

Ritlecitinib ( PF-06651600 )
Protocol B798106 [ADDRESS_1221107] be documented and 
reported to the sponso r. On a case -by-case basis, the sponsor may  make a determination as to 
whether sample integrity  has been compromised. Any  sample deemed outside of established 
stability , or of questionable integrit y, will be considered a protocol deviation.
Any data outsid e of the CYP2C9 genoty pi[INVESTIGATOR_874378].
8.5.2. Retained Research Samples for Genetics
A 4-mL blood sample optimized for DNA isolation Prep D1 will be collected according to 
the SoA, as local regulations and I RBs/ECs allow.
Retained Research Samples may  be used for research related to the study  intervention(s) and 
safet y biomarkers .Genes and other analy tes (eg, proteins, RNA, nondrug m etabolites) may  
be studied using the banked samples.
See Appendix 5 for information regarding genetic research. Details on processes for 
collection and shipment of these samples can be found in lab manual and other supporting 
documentation.
8.6. B iomarkers
Collection of samples for biomarker research is also part of this study . 
The following sample for biomarker research are required and will be collected from all 
participants in this study  as specified in the SoA:
A 10 mL  whole blood for serum (Prep B2) sample .
8.6.1. Retained Research Samples for Biomarkers
These Retained Research Samples will be collected in this study :
A 10 mL  whole blood for serum (Prep B2) sample will be collected according to the SoA , as 
local regulations and IRB/ECs allow.
Retained Research Samp les may  be used for research related to the study  intervention(s) and 
safet y biomarkers. Genes and other analy tes (eg, proteins, RNA, nondrug metabolites) may  
be studied using the banked samples.
See Appendix 5 for information regarding genetic research. Details on processes for 
collection and shipment of these samples can be found in lab manual and other supporting 
documentation.
8.7.Immunogenicity Assessments
Immunogenicit y assessments are not included in this stu dy.

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 528.8.Health Economics
Health e conomics/ medical resource utilization and health e conomics parameters are not 
evaluated in this study .
9.STATISTICAL CONSIDER
ATIONS
Detailed methodology  for summary  and statistical anal yses of the data collected in this study  
is outlined here and further detailed in a SAP, which will be maintained by  [CONTACT_456]. The 
SAP may  modify  what is outlined in the protocol where appropriate; however, any  major 
modifications of the primary  endpoint definitions or their anal yses will also be reflected in a 
protocol amendment.
9.1.Statistical Hypotheses
No statistical hy pothesis will be tested in this study .
9.2.Analysis Sets
For purposes of analy sis, the following anal ysis sets are defined:
Participant Analysis 
SetDescription
PK Parameter Evaluable The PK Evaluable population is defined as all participants 
treated who have at least [ADDRESS_1221108] quantifiable 
concentration ( Clast)Linear/Log trapezoidal rule

Ritlecitinib ( PF-06651600 )
Protocol B798106 [ADDRESS_1221109]+ (C last*/k el), where C last* is the 
predicted plasma concentration at the 
last quantifiable time point estimated 
from the log -linear regression analysis, 
and k elis the terminal phase rate 
constant calculated by a linear 
regression through at least [ADDRESS_1221110] occurrence
CL/F Apparent clearance Dose/AUC inf
Vz/F Apparent volume of distribution 
following oral administrationVz/F= Dose /(AUC inf*kel)
t½ Terminal plasma elimination half -life Log e(2)/k el, Only those data points 
judged to describe the terminal 
log-linear decline will be used in the 
regression
9.3.1. General Considerations
Methodology for summary  and statistical anal yses of the data collected in this study  is 
outlined here and further detailed in a SAP, which will be maintained by  [CONTACT_456]. The 
SAP may  modify  what is outlined in the protocol where appropriate, however, a ny major 
modifications of the primary  endpoint definitions or their anal yses will also be reflected in a 
protocol amendment.
9.3.2. Primary Endpoints
Natural log -transformed parameters AUC inf(if data permit, otherwise AUC last) and C max of
tolbutamide will be analyzed using a mixed effect model with treatment as a fixed effect and 
participant as a random effect. Estimates of the adjusted mean differences (Test -Reference) 
and corresponding 90% CI s will be obtained from the model.  The adjusted mean diff erences 
and 90% CIs for the differences will be exponentiated to provide estimates of the ratio of 
adjusted geometric means (Test/Reference) and 90% CI  for the ratios. Tolbutamide
administered alone will be the Reference treatment and tolbutamide co-admini stered with 
ritlecitinib will be the Test treatment.
Actual PK sampling times will be used in the derivation of PK parameters. The tolbutamide
AUC inf, AUC lastand C maxwill be listed and summarized descriptivel y by [CONTACT_3148].  

Ritlecitinib ( PF-06651600 )
Protocol B798106 [ADDRESS_1221111], CL/F, V z/F and t ½, as data permit, will be listed and 
summarized descriptively b y treatment. Plasma concentrations will be listed and summarized 
descriptivel y by [CONTACT_769084]. Individual participant and 
summary  profiles (mean and median plots) of the plasma concentration -time data will be 
plotted using actual and nominal times, respectively .
9.3.4. Other 
Safety Analyses
All safet y anal yses will be performed on the s afety population.
AEs, 
ECGs, BP , pulse rate , and safety  laboratory  data will be reviewed and summarized on 
an ongoing basis during the study  to evaluate the safet y of participant s. An y clinical 
laboratory , ECG, BP, and pulse rate abnormalities of potential clinical concern will be 
described. Safet ydata will be presented in tabular and/or graphical format and summarized 
descriptivel y, where appropriate.
Medical history  and phy sical examination and neurological examination information , as 
applicable, collected during the course of the study  will be c
onsidered source data and will 
not be required to be reported, unless otherwise noted. However, an y untoward findings 
identified on phy sical and/or neurological examination s conducted during the active 
collection period will be captured as AEs, if those fi ndings meet the definition of an AE. 
Data collected at screening that areused for inclusion/exclusion criteria, such as laboratory  
data, ECGs ,and vital signs , will be considered source data, and will not be required to be 
reported , unless otherwise noted
. Demographic data collected at screening will be reported .
9.3.5. Other Analyses 
Pharmacogenomic or biomarker data from Retained Research Samples may be collected 
during or after the trial and retained for future analyses; the results of such anal yses are not 
planned to be included in the CSR .
9.4.Interim Analyses
No formal interim anal ysis will be conducted for this study . As this is an open -label study ,
the sponsor may  conduct unblinded reviews of the data during the course of the study  for the 
purpose of safet y assessment, and/or support ingclinical development. 
9.5.Sample Size Determination
The following table presents the width of 90% confidence interval forapproximately n=12 
and different estimated effects of ritlecitinib on the pharmacokinetics of a single, oral dose of
tolbutamide .

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 55Table 5. Estimated 90% CIs for Different Underlaying Effects 
Parameter Estimated Effect
(100*Test/Reference)90% CI LB 90% CI UB 90% CI Width
AUC inf 70% 59.1% 82.9% 23.8%
75% 63.3% 88.8% 25.5%
80% 67.6% 94.7% 27.2%
85% 71.8% 100.7 % 28.9%
90% 76.0% 106.6 % 30.6%
95% 80.2% 112.5 % 32.3%
100% 84.4% 118.4 % 34.0%
105% 88.7% 124.3 % 35.7%
These calculations are based on the estimate of within -participant standard deviation of 0. 20
for tolbutamide log eAUC inf  as obtained from published studies .8,9,10

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 5610. SUPPORTING DOCUMENTA TION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from international guidelines including the 
Declarat ion of Helsinki and CIOMS International Ethical Guidelines ;
Applicable ICH GCP guidelines;
Applicable laws and regulations , including applicable privacy  laws .
The protocol, protocol amendments, I CD, SRSD(s) , and other relevant documents 
(eg,advertisements ) must be 
reviewed and approved by  [CONTACT_107095]/EC by  [CONTACT_107096]/EC before the study  is 
initiated.
Any amendments to the protocol will require IRB/EC approval before implementation of 
change s made to the study  design, except for changes necessary  to eliminate an immediate 
hazard to study  participants.
The investigator will be responsible for the following:
Providing written summaries of the status of the study  to the IRB/EC annually  or 
more f requently  in accordance with the requirements, policies, and procedures 
established by  [CONTACT_1201]/EC ;
Notify ing the IRB/EC of SAEs or other significant safet y findings as required by 
[CONTACT_1744]/EC procedures;
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 CFR, ICH GCP guidelines, the I RB/EC, European regulation 
536/2014 for clinical studies (if applicable), European Medical Device Regulation 
2017/745 for clinical device research (if applicable), and all other applicable local 
regulations .
[IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any area of the world, or if the investigator is aware of an y new 
information that might influence the evaluation of the benefits and risks of the study  
intervention , [COMPANY_007] should be informed immediately .
In addition, the investigator will inform [COMPANY_007] immediately  of any  urgent safet y measures 
taken b y the investigator to protect the study participant
s against an y immediate hazard, and 

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 57of an y serious breaches of this protocol or of ICH GCP guidelines that the investigator 
becomes aware of.
10.1.2. Informed Consent Process
The investigator or his/her representative will explain the nature of the study , including the 
risks and benefits, to the participant and answer all questions regarding the study .The 
participant should be given sufficient time and opportunity  to ask questions and to decide 
whether or not to participate in the trial.
Participants must be informed that their participation is voluntary . Participants will be 
required to sign a statement of informed co nsent that meets the requirements of 21 CFR 50, 
local regulations, ICH guidelines, privacy  and data protection requirements, where 
applicable, and the IRB/EC or study  center.
The investigator must ensure that each study  participant is fully  informed about the nature 
and objectives of the study, the sharing of data related to the study ,and possible risks 
associated with participation, including the risks associated with the processing of the 
participant ’s personal data. 
The participant must be informed tha t his/her personal study -related data will be used by  [CONTACT_20004]. The level of disclosure must also be 
explained to the participant.
The participant must be informed that his/her medical records may  be examined by [CONTACT_160439], by  
[CONTACT_6667]/EC members, and b y inspectors from regulatory authorities.
The investigator further must ensure that each study  participant is fully  informed about his or 
her right to access and correct his or her personal data and to withdraw consent for the 
processing of his or her personal data.
The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study  and the date the written consent was obtained.
The authorized person obtaining the informed consent must also sign the IC D
.
Participants must be reconsented to the most current version of the IC D(s) during their 
participation in the study .
A cop y of the IC D(s) must be provided to the participant.
10.1.3. Data Protection
All parties will comply  with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data.

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 58Participants’ personal data will be stored at the study  site in encry pted electronic and/or paper 
form and will be password protected or secured in a locked room to ensure that only  
authorized study  staff have access. The study  site will implement appro priate technical and 
organizational measures to ensure that the personal data can be recovered in the event of 
disaster. In the event of a potential personal data breach, the study site will be responsible for 
determining whether a personal data breach has in fact occurred and, if so, providing breach 
notifications as required by  [CONTACT_2371].
To protect the rights and freedoms of participants with regard to the processing of personal 
data, participants will be assigned a single, participant -specific numerical code. Any 
participant records or data sets that are transferred to the sponsor will contain the numerical 
code; participant names will not be transferred. All other identifiable data transferred to the 
sponsor will be identified by  [CONTACT_20007], participant- specific code. The study  site will 
maintain a confidential list of participant s who participated in the study, linking each 
participant ’s numerical code to his or her actual identity and medical record identification . In 
case of data transfer, the sponsor w ill protect the confidentiality  of participants’ personal data 
consistent with the c linical study agreement and applicable privacy  laws.
10.1.4. Committees Structure
[IP_ADDRESS]. Data Monitoring Committee
This study  will not use a DMC. 
10.1.5. Dissemination of Clinical Study Data
[COMPANY_007] fulfills its commitment to publicly  disclose clinical study  results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the EudraCT , and/or 
www.pfizer.com, and other public registries in accordance with applicable local 
laws/regulations. In addition, [COMPANY_007] reports study  results outside of the requirements of local 
laws/regulations pursuant to its SOPs.
In all cases, stud y results are reported b y [COMPANY_007] in an objective, accurate, balanced, and 
complete manner and ar e reported regardless of the outcome of the study  or the country  in 
which the study  was conducted.
www.clinicaltrials.gov
[COMPANY_007] posts clinical trial results on www.clinicaltrials.gov for [COMPANY_007]- sponsored interventional 
studies (conducted in patients) that evaluate the safety  and/or efficacy  of a product, 
regardless of the geographical location in which the study  is conducted. These r esults are 
submitted for posting in accordance with the format and timelines set forth by  [CONTACT_874389].
EudraCT
[COMPANY_007] posts clinic al trial r esults on EudraCT for [COMPANY_007] -sponsored interventional studies in 
accordance with the format and timelines set forth by  [CONTACT_20009].

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 59www.pfizer.com
[COMPANY_007] posts public disclosure s ynopses (CSR synopses in which an y data that could be used 
to identify  individual participants have been removed) on www.pfizer.com for 
[COMPANY_007] -sponsored interventional studies at the same time the corresponding study  results are
posted to www.clinicaltrials.gov .
Documents within marketing authorization packages/submissions
[COMPANY_007] complies with the European Union Policy  0070, the proactive publication of clinical 
data to the EMA website.   Clinical data, under Phase 1 of this policy ,includes clinical 
overviews, clinical summaries, C SRs, and appendices containing the protocol and protocol 
amendments, sample CRF s, 
and statistical methods. Clinical data, under Phase 2 of this 
policy ,includes the publishing of individual participant data. Policy  0070 applies to new 
marketing authorization applications submitted via the centraliz ed procedure since 
01January 2015 and applications for line extensions and for new indications submitted via 
the centralized procedure since 
01 July  2015.
Data Sharing
[COMPANY_007] provides researchers secure access to patient-level data or full CSRs f or the purposes 
of “bona -fide scientific research” that contribute sto the scientific understanding of the 
disease, target, or compound class. [COMPANY_007] will make available data from these trials 
24months after study  completion. Patient- level data will be an onymized in accordance with 
applicable privacy  laws and regulations. CSRs will have personally  identifiable information 
redacted.
Data requests are considered from qualified researchers with the appropriate competencies to 
perform the proposed analy ses. Re search teams must include a biostatistician. Data will not 
be provided to applicants with significant conflicts of interest, including individuals 
requesting access for commercial/competitive or legal purposes.
10.1.6. Data Quality Assurance
All participant data relating to the stud y will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically  (eg, laboratory  data). The investigator is 
responsible for verify ing that data entries are accurate and correct by  [CONTACT_874390].
Guidance on completion of CRFs will be provided in the CRF Completion Requirements 
document.
The investigator must ensure that the CRFs are securel y stored at the study site in encrypted 
electronic and/or paper form and are password protected or secured in a locked room to 
prevent access b y unauthorized third parties.

Ritlecitinib ( PF-06651600 )
Protocol B798106 [ADDRESS_1221112] permit study -related monitoring, audits, IRB/EC review, and 
regulatory  agency  inspections and provide direct access to source data docume nts.This 
verification may  also occur after study  completion. I t is important that the investigator(s) and 
their relevant personnel are available during the monitoring visits and possible audits or 
inspections and that sufficient time is devoted to the pro cess.
Monitoring details describing strategy, including definition of study  critical data items and 
processes (eg, risk
-based initiatives in operations and quality  such as risk management and 
mitigation strategies and analytical risk-based monitoring), met hods, responsibilities ,and 
requirements, including handling of noncompliance issues and monitoring techniques 
(central, virtual, or on- site monitoring) ,are provided in the data management plan and IQMP
maintained and utilized by  [CONTACT_36613] .
The sponsor or designee is responsible for the data management of this study ,including 
quality  checking of the data.
Records and documents, including signed IC Ds, pertaining to the conduct of this study  must 
be retained b y the investigator for 15years af ter study  completion unless local regulations or 
institutional policies require a longer retention period. No records may  be destroy ed during 
the retention period without the written approval of the sponsor. No records may  be 
transferred to another locatio n or part y without written notification to the sponsor. The 
investigator must ensure that the records continue to be stored securel y for aslong as they  are 
maintained.
When participant data are to be deleted, the investigator will ensure that all copi[INVESTIGATOR_78245] y deleted from all systems.
The investigator(s) will notify  the sponsor or its agents immediately  of any  regulatory  
inspection notification in rel
ation to the study . Furthermore, the investigator will cooperate 
with the sponsor or its agents to prepare the investigator site for the inspection and will allow 
the sponsor or its agent, whenever feasible, to be present during the inspection. The 
investigator site and investigator will promptly  resolve any  discrepancies that are identified 
between the stud y data and the participant's medical records. The investigator will promptly  
provide copi[INVESTIGATOR_19946]. Befo re response 
submission to the regulatory  authorities, the investigator will provide the sponsor or its 
agents with an opportunity to review and comment on responses to an y such findings.
10.1.7. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected. Source documents are filed at the investigator site.
Data reported on the CRF or entered in the eCRF that are from source documents must be 
consistent with the source documents or the discrepancies must be explained . The 
investigator may  need to request previous medical records or transfer records, depending on 
the study . Also, current medical records mu st be available.

Ritlecitinib ( PF-06651600 )
Protocol B798106 [ADDRESS_1221113] maintain accurate documentation (source data) that supports the 
information entered in the CRF.
Study  monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by  [CONTACT_1191], complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study  is 
being conducted in accordance with the currently  approved protocol and any  other study  
agreements, I CH GCP guidelines, and all appl icable regulatory  requirements.
10.1.8. Study and Site Start and Closure
The study  start date is the date on which the clinical study  will be open for recruitment of 
participants.
The first act of recruitment is the date of the first participant’s first visit and will be the study  
start date.
The sponsor designee reserves the right to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of the sponsor. Study  sites will be closed upon study  
completion. A study  site is conside red closed when all required documents and study  
supplies have been collected and a stud y-site closure visit has been performed.
The investigator may  initiate study -site closure at any  time upon notification to the CRO if 
requested to do so b y the responsible IRB/EC or if such termination is required to protect the 
health of study  participants.
Reasons for the earl y closure of a stud y site b y the sponsor may include but are not limited 
to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/EC or local health authorities, the sponsor's procedures, or GCP guidelines;
Inadequate recruitment of participants by  [CONTACT_093];
Discontinuation of further study  intervention development .

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 62If the stud y is prematurely termina ted or suspended, the sponsor shall promptly  inform the 
investigators, the ECs/IRBs, the regulatory  authorities, and any  CRO (s) used in the study  of 
the reason for termination or suspension, as specified by  [CONTACT_20013]. The investigator shall promptly  inform the participant and should assure 
appropriate 
participant therapy  and/or follow -up.
Study  termination is also provided for in the clinical study  agreement. If there is any  conflict 
between the contract and this protocol, the c ontract will control as to termination rights.
10.1.9. Publication Policy
The results of this study  may  be published or presented at scientific meetings b y the 
investigator after publication of the overall study  results or 1year after the end of the stud y 
(or study  termination), whichever comes first. 
The investigator agrees to refer to the primary  publication in any  subsequent publications ,
such as secondary manuscripts, and submit s all manuscripts or abstracts to the sponsor 
30days before submission. This allows the sponsor to protect proprietary  information and to 
provide comments and the investigator will, on request, remove an y previously  undisclosed 
confidential information before disclosure, except for an y stud y-or [COMPANY_007] -intervention 
related information necessary  for the appropriate scientific presentation or understanding of 
the study  results.
For all publications relating to the stud y, the investigator will compl y with recognized ethical 
standards concerning publications and authorship, including those established by  [CONTACT_19483].
The sponsor will comply  with the requirements for publication of the over all study  results 
covering all i nvestigator sites. In accordance with standard editorial and ethical pract ice, the 
sponsor will support publication of multicenter studies only  in their entirety and not as 
individual site data. In this case, a coordinating investigator [INVESTIGATOR_78246].
Authorship of publications for the overall study  resu lts will be determined by  [CONTACT_78275] I nternational Committee of Medical Journal Editors authorship 
requirements. 
If publication is addressed in the clinical study  agreement, the publication policy  set out in 
this section will not ap
ply.
10.1.10. Sponsor’s Qualified Medical Personnel
The contact [CONTACT_1133]'s appropriately qualified medical personnel for the 
study  is documented in the study  contact [CONTACT_874391] .
To facilitate access to appr opriatel y qualified medical personnel for studyrelated medical 
questions or problems, participants are provided with an Emergency  Contact [CONTACT_74057] (ECC) at 

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 63the time of informed consent. The ECC contains, at a minimum, (a) protocol and study  
intervention identi fiers, (b) participant’s stud y identification number, (c) site emergency 
phone number active 24 hours/day , [ADDRESS_1221114] s 
between the investigator, site staff, and study team. The ECC is to be used by [CONTACT_78277] y only , as a means of reaching the investigator 
or site staff related to the care of a participant.

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 6410.2. Appendix 2: Clinical Laboratory Tests
The followi ng safet y labora tory tests ( Table 6) will be performed at times defined in the SoA
section of this protocol. Additional laboratory  results may be reported on these samples as a 
result of the method of ana lysis or the t ype of analy zer used by  [CONTACT_20019] ,or as 
derived from calculated values. These additional tests would not require additional collection 
of blood. Unscheduled clinical laboratory  measurements may  be obtained at any  time during 
the study  to assess any  perceived safety  concerns.
Table 6. Protocol -Required Safety Laboratory Assessments
Hem atology Chemistry (fasting) Urinalysis Other
Hem oglobin
Hem atocrit
RBC count
MCV
MCH
MCHC
Platelet count
WBC count
Total neutrophils (Abs 
and %)
Eosinophils (Abs and %)
Monocytes (Abs and %)
Basophils (Abs and %)
Lymphocytes (Abs and 
%)BUN/urea and 
creatinine
Glucose (fasting)
Calcium
Sodium
Potassium
Chloride
Total CO 2(bicarbonate)
AST, ALT
Total bilirubin
Alkaline phosphatase
Albumin
Total protein
Uric acid
CK
Total cholesterol
HDL cholesterol
LDL cholesterol
(calculated)
TriglyceridespH
Glucose (qual)
Protein (qual)
Blood (qual)
Ketones
Nitrites
Leukocyte esterase
Urobilinogen
Urine bilirubin
MicroscopyaCOVID -19 testing
FSHb
Pregnancy test (β -hCG)d
HBsAge
HBcAbe
HCVAbe
HIVQuan tiFERON®- TB 
Gold Teste
Urine drug screeningc
eGFR -CKD -EPIe
Viral screenf
Testing as indicated (reflex 
testing; refer to Section 10.8.1
and Section 10.8.2 for 
guidance/criteria) :
FACS -TBNK
Urine myoglobin 
Section 10.8.1 .
Additional 
Assessments for Hy’s 
Law:
AST, ALT  (repeat)
Total bilirubin (repeat)
Albumin (repeat)
Alkaline phosphatase 
(repeat)
Direct bilirubin
Indirect bilirubin
GGT
PT/INR
Total bile acids

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 65Table 6. Protocol -Required Safety Laboratory Assessments
Hem atology Chemistry (fasting) Urinalysis Other
a.Only if urine dipstick is positive for blood, protein, nitrites, or leukocyte esterase.
b.At Screening for confirmation of postmenopausal status only.
c.At Screening and Admission.  The minimum requirement for drug screening includes cocaine, THC, 
opi[INVESTIGATOR_858]/opi[INVESTIGATOR_2438], benzodiazepi[INVESTIGATOR_1651], and amphetamines (others are site and study specific).
d.Serum -hCG for female participants of childbearing potential according to Schedule of Activ ities.
e.Com plete at screening . Previous testing for QuantiFERON ®-TB Gold Test will be accepted if 
completed within 12 w eeks prior to baseline . Otherwise should be completed at screening and results 
available prior to Day -1.
f.A serum sample will be collected at baseline and submitted to the central lab. The sample will be stored 
and analyzed at a later date only at the sponsor’s request. In certain cases of suspected viral infection (eg, 
disseminated herpes zoster or varicella), the sponsor may request to analyze the sample to determine if 
the subject had exposure to that virus.
The investigator must review the laboratory  report, document this review, and record an y 
clinically  relevant changes occurring during the study in the AE section of the CRF.
Participants may  undergo random urine drug testing at the discretion of the investigator. 
Drug testing prior to dosing must be neg ative for participants to receive investigational 
product

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 6610.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is an y untoward medical occurrence in a patient or clinical study  
participant, temporall y associated with the use of study intervention, whether or not 
considered related to the study  intervention.
NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), sy mptom, or disease (new or exacerbated) 
temporally associated with the use of study  intervention.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (eg, ECG, radiological scans, vital sign measurements), 
including those that worsen from baseline, considered clinicall y significant in the 
medical and scientific judgment of the investigator.   Any abnormal laboratory test 
results that meet an y of the condition s below must be recorded as an AE:
Is associated with accompany ing s ymptoms
;
Requires additional diagnostic testing or medical/surgical intervention ;
Leads to a change in study  dosing (outside of any  protocol -specified dose 
adjustments) or discontinuation from the study , significant additional 
concomitant drug treatment, or other therap y.
Exacerbation of a chronic or intermittent preexisting condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or dia gnosed after stud y intervention administration even 
though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected over dose of either study  
intervention or a concomitant medication. Overdose per se will not be reported as 
an AE/SAE unless it is an intentional overdose taken with possible 
suicidal/self-harming intent. Such overdoses should be reported regardless of 
sequelae .

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 67Events NOT Meeting the AE Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  [CONTACT_11009]’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of preexisting disease(s) or co ndition(s) present 
or detected at the start of the study that do not worsen.
10.3.2. Definition of SAE
An SAE is defined as any untoward medical occurrence that, at any dose , meets one 
or more of the criteria listed below:
a.Results in death
b.Is life -threatening
The term “life-threatening ”in the definition of “serious” refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event that
hypothetically  might have caused death if it were more severe.
c.Require s inpatient hospi[INVESTIGATOR_22770], hospi[INVESTIGATOR_19949] (usually 
involving at least an overnight stay ) at the hospi[INVESTIGATOR_19950]/or tre atment that would not have been appropriate in the phy sician’s office or 
outpatient setting. Complications that occur during hospi[INVESTIGATOR_1084]. If a 
complication prolongs hospi[INVESTIGATOR_9236], the event is 
serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary , the 
AE should be considered serious.
Hospi[INVESTIGATOR_5187] a preexisting condition that did not worsen 
from baseline is not considered an AE.

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 68d.Results in persistent or significant disability/incapacity
The term disability means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
signifi cance such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, sprained ankle) which may  interfere with or 
prevent every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/bir th defect
f.Is a suspected transmission via a [COMPANY_007] product of an infectious agent, pathogenic 
or non- pathogenic, is considered serious.  
The event may  be suspected from clinical s ymptoms or laboratory  findings indicating 
an infection in a participant exposed to a [COMPANY_007] product. The terms “suspected 
transmission” and “transmission” are considered sy nony mous. These cases are 
considered unexpected and handled as serious expedited cases b y pharmacovigilance 
personnel. Such cases are also considered for re porting as product defects, if 
appropriate.
g.Other situations:
Medical or scientific judgment should be exercised by [CONTACT_874392]-threatening or result in death or 
hospi[INVESTIGATOR_874379]. These events should usually  be consid ered serious.
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug 
depend ency  or drug abuse.
10.3.3. Recording/Reporting and Follow -up of AE sand/or SAE sDuring the Active 
Collection Period
AE and SAE Recording /Reporting
The table below summarizes the requirements for recording AEs on the CRF and for 
reporting SAEs on the CT SAE Report Form to [COMPANY_007] Safet ythroughout the active 
collection period . These requirements are delineated for 3 ty pes of events: (1) SAEs; (2) 

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 69nonserious AEs; and (3) exposure to the study  intervention under stud y during pregnancy  
or breastfee ding, and occupational exposure. 
It should be noted that the CT SAE Report Form for reporting of SAE information is not 
the same as the AE page of the CRF. When the same data are collected, the forms must be 
completed in a consistent manner. AEs should be recorded using concise medical 
terminology  and the same AE term should be used on both the CRF and the CT SAE 
Report Form for reporting of SAE information.
Safety Event Recorded on the CRF Reported on the CT SAE 
Report Form to [COMPANY_007] 
Safety Within 24 Hour s of 
Awareness
SAE All All
Nonserious AE All None
Exposure to the study  
intervention under stud y 
during pregnancy  or 
breastfeeding, and 
occupational exposureAll AEs/SAEs associated 
with exposure during 
pregnancy  or breastfeeding
Note:   Instances of EDP or 
EDB not associated with an 
AE or SAE are not captured 
in the CRF.All instances of EDP are 
reported (whether or not 
there is an associated 
SAE)*
All instances of EDB are 
reported (whether or not 
there is an associated 
SAE). **
Environmental or 
occupational exposure to 
the product under stud y 
to a non -participant (not 
involving EDP or EDB).None.  Exposure to a study  
non-participant is not 
collected on the CRF.The exposure (whether or 
not there is an associated 
AE or SAE) must b
e 
reported.***
*EDP (with or without an associated AE or SAE): any pregnancy information is reported to 
[COMPANY_007] Safety using CT SAE Report Form and EDP Supplemental Form; if the EDP is 
associated with an SAE, then the SAE is reported to [COMPANY_007] Safety using the CT SAE Report 
Form. 
** EDB is reported to [COMPANY_007] Safety using the CT SAE Report Form which w ould also include 
details of any SAE that might be associated w ith the EDB. 
***Environmental or Occupational exposure: AEs or SAEs associated with occupational exposure 
are re ported to [COMPANY_007] Safety using the CT SAE Report Form. 
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory  reports, and diagnostic 
reports) related to the event.

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 70The investigator will then record all relevant AE/SAE information in the CRF.
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to [COMPANY_007] Safety  in lieu of completion of the CT SAE Report 
Form /AE/SAE CRF page.
There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_007] Safety .In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copi[INVESTIGATOR_874380] .
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual signs/sy mptoms) will be documented as the AE/SAE .
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories: 
Mild: Asymptomatic or mild sy mptoms; clinical or diagnostic observations only ; 
intervention not indicated.
Moderate: Minimal, local or noninvasive intervention indicated; limiting age -
appropriate instrumental ADL. Instrumental ADL refers to preparing meals, 
shoppi[INVESTIGATOR_3112], using the telephone, managing money , etc.
Severe: Severe or medically  significant but not immediately  life-threatening; 
hospi[INVESTIGATOR_3111]; disabling, limiting self 
care ADL. Self care ADL refers to bathing, dressing and undressing, feeding self, 
using the toilet, taking medications, and not bedridden.
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE/SAE .The investigator will use clinical judgment 
to determine the relationship.
A “reasonable possibility” of a relationship conveys that there are facts, eviden ce, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 71Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to stud y intervention 
administration, will be considered and investigated.
The investigator will also consult the IB and/or product information, for marketed 
products, in his/her assessment.
For each AE/SAE, the investigator must document in the medical notes tha t he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor. However, it is 
very important t hat the investigator always make an assessment of causality 
for every event before the initial transmission of the SAE data to the sponsor .
The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information and send a nSAE follow -upreport with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
If the investigator does not know whether or not the study  intervention caused the 
event, then the event will be handled as “related to study  intervention ” for reporting 
purposes, as defined b y the sponsor . In addition, if the investigator determines that 
an SAE is associated with study  procedures, the investigator must record this 
causal relationship in the source documents and CRF, and report such an 
assessment in the dedicated section of the CT SAE Report Form and in accordance 
with the SAE reporting requirements.
Follow -up of AEs and SAEs
The investigator is obligated to perform or arrange for the cond uct of supplemental 
measurements and/or evaluations as medically  indicated or as requested by  [CONTACT_55900]/or causalit y of the AE or SAE as fully as 
possible. This may  include additional laboratory  tests or investigations, 
histop athological examinations, or consultation with other healthcare providers .
If a participant dies during participation in the study or during a recognized 
follow -up period, the investigator will provide [COMPANY_007] Safet y with a cop y of any 
postmortem findings including histopathology .

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 72New or updated information will be recorded in the origina lly submitted 
documents.
.
The investigator will submit any  updated SAE data to the sponsor within 24 hours 
of receipt of the information.
10.3.4. Reporting of SAEs
SAE Reporting to [COMPANY_007] Safety via an Electronic Data Collection Tool
The primary  mechanism for reporting an SAE to [COMPANY_007] Safety will be the 
electronic data collection tool.
If the electronic s ystem is unavailable, then the site will use the paper SAE data 
collection tool ( see next section) in order to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem as soon as the data
become available.
After the stud y is completed at a given site, the electronic data collection tool will 
be taken off -line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported SAE after the electronic data collection tool has been 
taken 
off-line, then the site can report this information on a paper SAE form (see 
next section) or to [COMPANY_007] Safety  by [CONTACT_756].
SAE Reporting to [COMPANY_007] Safety via CT SAE Report Form
Facsimile transmission of the CT SAE Report Form is the preferred method to 
transmit this information to [COMPANY_007] Safety .
In circumstances when the facsimile is not working , notification by  [CONTACT_20021] a cop y of the CT SAE Report Form sent by  [CONTACT_20022].
Initial not ification via telephone does not replace the need for the investigator to 
complete and sign the CT SAE Report Form pages within the designated reporting 
time frames.

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 7310.4. Appendix 4: Contraceptive and Barrier Guidance
10.4.1. Male Participant Reproductive Inc lusion Criteria
No contraception methods are required for male participants in this study  based on the 
following considerations:
Ritlec itinib is not likely  to transfer to a partner through semen at pharmacologicall y 
relevant blood levels .
According to the tolbutamide USPI [CONTACT_3031]5, there is no requirement for male 
contraceptive use during treatment.
10.4.2. Female Participant Reproductive Inclusion Crite ria
A female participant is eligible to participate if she is not pregnant or breastfeeding, and at 
least 1 of the following conditions applies:
Is not a WOCBP (see definitions below inSection 10.4.3).
OR
Is a WOCBP and using a contraceptive method that is highly
 effective (with a failure 
rate of <1% per year), preferably with low user dependency , as described below
during the intervention period and for at least [ADDRESS_1221115] dose of study  
intervention ,which corresponds to the time needed to eliminate any  reproductive 
safet y risk of the study  intervention(s) .The investigator should evaluate the 
effectiveness of the contraceptive method in relationship to the first dose of study  
intervention.
A WOCBP a grees not to donate eggs (ova, oocy tes) for the purpose of reproduction 
during this period and for at least 28daysafter the last dose ofstudy  intervention .
The investigator should evaluate the effectiveness of the contraceptive method in 
relationship to the first dose of study  intervention.
The investigator is responsible for review of medical history , menstrual history , and recent 
sexual activity  to decrease the risk for inclusion of a woman with an earl y undetected 
pregnancy . 
10.4.3. Woman of Childbearing Potential
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below).
If fertility  is un clear (eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed before the 
first dose of study  intervention, additional evaluation should be 
considered.

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 74Women in the following categories are notconsidered WOCBP:
1.Premenopausal female with 1 of the following:
Documented h ysterectomy ;
Documented bilateral salpi[INVESTIGATOR_1656] ;
Documented bilateral oophorectom y.
For individuals with permanent infertility  due to an alternate medical cause other than 
the above, (eg, mullerian agenesis, andr ogen insensitivity ), investigator discretion 
should be applied to determining study  entry .
Note: Documentation for any  of the above categories can come from the site 
personnel’s review of the participant’s medical records, medical examination, or 
medical h istory  interview. The method of documentation should be recorded in the 
participant’s medical record for the stud y.
2.Postmenopausal female .
A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. I n addition, 
A high FSH level in the postmenopausal range must be used to confirm a 
postmenopausal state in women under 60 years old and not using hormonal 
contraception or HRT .
For women using HRT, FSH should be measured after an appropriate washout 
of HRT (at least [ADDRESS_1221116] dose of HRT). HRT must be 
discontinued at least [ADDRESS_1221117] dose of ritlecitinib.
A female whose menopausal status is in doubt will be required to use o ne of the 
allowed nonhormonal highl y effective contraception methods.
10.4.4. Contracepti onMethods
Contraceptive use b y men or women should be consistent with local availability /regulations 
regarding the use of contraceptive methods for those participating in clinical trials.
Highly Effective Methods That Have Low User Dependency 
1.Non-hormonal Intrauterine device (IUD).
2.Bilateral tubal occlusion or ligation .

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 753.Vasectomized partner.
Vasectomized partner is a highl y effective contraceptive method provided that the 
partner is the sole sexual partner of the WOCBP and the absence of sperm has 
been confirmed. If not, an additional highl y effective method of contraception 
should be used. The spermatoge nesis cy cle is approximately  90 day s.
Highly Effective Methods That Are User Dependent
1.Sexual abstinence.
Sexual abstinence is considered a highl y effective method only  if defined as 
refraining from heterosexual intercourse during the ent ire period of risk associated 
with the study  intervention. The reliability  of sexual abstinence needs to be evaluated 
in relation to the duration of the study and the preferred and usual lifest yle of the 
participant.

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 7610.5. Appendix 5: Genetics
Use/Analysis of DN A
Genetic variation may  impact a participant’s response to study  intervention, 
susceptibility  to, and severity  and progression of disease. Therefore, where local 
regulations and IRB s/ECsallow, a blood sample will be collected for DNA anal ysis.
The scope of the genetic research may  benarrow (eg, 1or more candidate genes ) or
broad (eg,the entire genome ),as appropriate to the scientific question under 
investigation.
The samples may  be analy zed as part of a multistudy  assessment of genetic factors 
involve d in the response to study  intervention or study  interventions of this class to 
understand treatments for the disease(s) under study  or the disease(s) themselves.
The results of genetic analy ses may  be reported in the CSR or in a separate study  
summary , ormay be used for internal decision making without being included in a 
study  report.
The sponsor will store the DNA samples in a secure storage space with adequate 
measures to protect confidentiality . 
The samples will be retained as indicated:
Retained samples will be stored indefinitely  or for another period as per local 
requirements.  
Samples for specified genetic anal ysis (see Section 8.5.1) will be stored for up to  
3 years after regulatory  approval or other period as per local requirements .
Participant s may  withdraw their consent for the storage and/or use of their Retained 
Research Samples at an y time by  [CONTACT_7328] a request to the investigator; in this case, 
any remaining material will be destroy ed. Data already  generated from the samples 
will be retained to protect the integrit y of existing anal yses.  
Samples for genetic research will be labeled with a code. The key  between the code 
and the participant’s personally  identify ing information (eg, name, address) will be 
held securely  at the study site.

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 7710.6. Appendix 6: Liver Safety: Suggested Actions and Follow- up Assessments
Potential Cases of Drug- Induced Liver Inju ry
Humans exposed to a drug who show no sign of liver injury  (as determined by  [CONTACT_20023]) are termed “tolerators,” while those who show transient liver injury , but adapt 
are termed “adaptors.” In some participant s, transaminase elevations are a harbinger of a 
more serious potential outcome. These participant s fail to adapt and therefore are 
"susceptible" to progressive and serious liver injury, commonl y referred to as DILI . 
Participant s who experience a transaminase elevation above 3 ×ULN should be monitored 
more frequently  to determine if they  are an “adaptor” or are “susceptible.”
In the majority  of DILI cases, elevations in AST and/or ALT precede TBili elevations 
(>2×ULN) b y several day s or weeks. The increase in TBili ty pi[INVESTIGATOR_874381] s while AST/ALT 
is/are still elevated above 3 ×ULN (ie, AST/ALT and TBili values will be elevated within 
the same lab oratory sample). In rare instances, by [CONTACT_22858], 
AST/AL T values might have decreased. This occurrence is sti ll regarded as a potential DILI. 
Therefore, abnormal elevations in either AST OR AL T in addition to TBili that meet the 
criteria outlined below are considered potential DILI (assessed per Hy ’s law criteria) cases
and should alway s be considered important m edical events, even before all other possible 
causes of liver injury  have been excluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the 
participant ’s individual baseline values and underly ing conditions. Participant s who present 
with the following laboratory  abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to definitively  determine the etiology  of the abnormal laboratory  values:
Participant s with AST/ALT and TBili baseline values within the normal range who 
subsequently  present with AST OR AL T values >3 ×ULN AND a TBili value 
>2× ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not available.
For participant s with baseline AST OR ALT ORTBili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values >2 times the baseline values AND >3 ×ULN; or >8 ×ULN (whichever is 
smaller).
Preexisting values of TBili above the normal range: TBili level increased from 
baseline value b y an amount of at least 1 × ULN orif the value reaches 
>3×ULN (whichever is sma ller).

Ritlecitinib ( PF-06651600 )
Protocol B798106 [ADDRESS_1221118]/AL T and TBili separated b y more than a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor.  
The participant should return to the investigator site and be evaluated as soon as possible, 
preferabl y within [ADDRESS_1221119] and AL T and TBili for suspected cases of 
Hy’s law, additional laboratory  tests should include albumin, CK, direct and indirect 
bilirubin, GGT, PT/I NR, total bile acids, and alkaline phosphatase. Consideration should also 
be given to drawing a separate tube of clotted blood and an anticoagulated tube of blood for 
further testing, as needed, for further contemporaneous anal yses at the time of the recognized 
initial abnormalities to determine etiology . A detailed his tory, including relevant information, 
such as review of ethanol, acetaminophen /paracetamol (either b y itself or as a coformulated 
product in prescription or over -the-counter medications) , recreational drug, supplement 
(herbal) use and consumption, family  history , sexual history , travel history, history  of contact 
[CONTACT_4490] a jaundiced person, surgery , blood transfusion, history  of liver or allergic disease, and 
potential occupational exposure to chemicals, should be collected. Further testing for acute 
hepatitis A, B, C, D, and E infection and liver imaging (eg, biliary  tract) and collection of 
serum sample sfor acetaminophen /paracetamol drug and/or protein adduct levels may  be 
warranted. 
All cases demonstrated on repeat testing as meeting the laboratory  criteri a of AST/AL T and 
TBili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the LFT abnormalities has yet been found.  
Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availabil ity of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have excluded an alternative etiology .

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 7910.7. Appendix 7: ECG Findings of Potential Clinical Concern
ECG Findings T hat May Q ualify as Adverse Events
Marked sinus bradycardia (rate <40 bpm) lasting minutes.
New PRinterval prolongation >280 ms ec.
New prolongation of QTcF to >480 msec (absolute) or by≥60msecfrom 
baseline .
New -onset atrial flutter or fibrillation, with controlled ventricular response rate: ie, 
rate<120 bpm .
New -
onset typeI second - degree (Wenckebach) AVblock of >30 seconds’
duration.
Frequent PVCs , triplets , orshort intervals (<30 seconds) of consecutive 
ventricular complexes .
ECG Findings T hat May Q ualify as Serious Adverse Events
QTcF prolongation >500 ms ec.
New ST- T changes suggestive of my ocardial ischemia .
New -onset l eft bundle branch block (QRS >120 ms ec).
New -onset right bundle b ranch block (QRS >120 msec).
Symptomatic bradycardia .
Asystole:
In awake, s ymptom -free participant s in sinus rhy thm, with documented 
periods of as ystole ≥3.0 seconds or an y escape rate <40 bpm, or with an 
escape rh ythm that is below the AV node. 
In awake, s ymptom -free participant s with atrial fibrillation and brad ycardia 
with [ADDRESS_1221120] 5 seconds or longer. 
Atrial f lutter or fibrillation, with rapid ventricular response r ate: rapid = rate 
>120 bpm.
Sustained s upraventricular tachycardia (rate >120 bpm) (“sustained ”= short 
duration with relevant symptoms or lasting >1 minute) .

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 80Ventricular r hythms >30 seconds’ duration, including idioventricular rhy thm 
(heart rate <40 bpm), accelerated idioventricular rhy thm ( HR>40bpm to
<100 bpm), and monomorphic/poly morphic ventricular tach ycardia (HR 
>100 bpm (such as torsades de pointes) ).
Type IIsecond -degree (Mobitz II)AVblock.
Complete (third
-degree) heart block.
ECG Findings T hat Q ualify as SAEs
Change in pattern suggestive of new m yocardial infarction .
Sustained ventricular t achy arrhy thmias (>30 seconds ’duration) .
Second- or third -degree AV block requiring pacemaker placement.
Asystolic pauses requiring pacemaker placement.
Atrial flutter or fibrillation with rapid ventricular response requiring 
cardioversion .
Ventricular fibrillation/ flutter .
At the discretion of the investigator, an y arrh ythmia classified as an adverse 
experience .
The enumerated list of major events of potential clinical concern are recommended as “alerts ”or 
notifications from the core ECG lab oratory to the investigator and [COMPANY_007] study team ,and not to be 
considered as all inclusive of what to be reported as AEs/SA Es.

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 8110.8. Appendix 8: Guidelines for Participant Safety Monitoring and Discontinuation
These guidelines for participant safet y monitoring and discontinuation are to be applied to al l 
participants in Study  B79810 69.Additional individual participant monitoring is at the 
discretion of the investigator and dependent on any  perceived safety  concerns. Unscheduled 
clinical labs may  be obtained at an y time during the study  to assess such concerns, and a
participant may  be withdrawn at an y time at the 
discretion of the investigator.
10.8.1. Participant Safety Monitoring
All potential treatment -related events of rash will be followed up until resolution or 
agreement with [COMPANY_007].
In the case of a positive urine pregnancy  test, the par ticipant will have investigational product
interrupted and a serum sample collected on the same day  (or as soon as possible) and 
submitted to the laboratory  for pregnancy  testing.
The following laboratory abnormalities require re -testing until resolution or agreement 
with [COMPANY_007]:
Laboratory 
VariableLaboratory Value Re-testing 
Timeframec
Hem atology
Absolute Neutrophil 
Count<1000/mm3 (<1.0 ×109/L) 24-48 hours
Hem oglobin <10.0 g/dL (<6.21 mmol/L or <100 g/L) 
OR
Decrease of ≥2.0 g/dL from baseline24-48 hours
Platelet count <100,000/mm3 (<100.0 ×109/L) 24-48 hours
ALCa<600/mm3 (<0.6 ×109/L) 24-48 hours
Serum Che mistry
CKb>3×ULN 24-[ADDRESS_1221121] See Appendix 6 for potential cases of drug -induced liver 
injury.24-48 hours
ALT See Appendix 6 for potential cases of drug -induced liver 
injury.24-48 hours
TBili See Appendix 6 for potential cases of drug -induced liver 
injury.24-48 hours
a.Participants with ALC <500/mm3(0.5×109/L) will be reflex -tested for FACS -TBNK until the ALC
resolves or stabilizes at a level acceptable to the investigator and sponsor.
b.In addition to re -testing creatinine kinase >3 ×ULN, urine myoglobin will be performed as reflex 
testing for any participant with CK >10×ULN .
c.Timefram e is based on the awareness of the abnormal results.

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 8210.8.2. Participant Discontinuation Criteria
Treatment will be discontinued and the participant withdrawn from this study for:
Adverse Events:
Serious infections, defined as an y infection (viral, bacterial, and fungal) requiring 
parenteral antimicrobial therap y or hospi[INVESTIGATOR_773309];
Treatment -related SAEs;
Other serious or severe AEs, at the d iscretion of the investigator or sponsor.
ECG Findings:
Confirmed QTcF >500 milliseconds;
Confirmed increase from baseline in QTcF of >60 milliseconds.
Laboratory Abnormalities:
All thefollowing laboratory  abnormalities require discontinuation if they are
confirmed by [CONTACT_874393]. Refer to the re- testing timeframes for laboratory  abnormalities in 
Section 10.8.1 .
ANC <750/mm3(<0.75 × 109/L);
Hemoglobin <9.0 g/dL (<5.59 mmol/L  or <90 g/L) or a decrease of >30% fr om 
baseline (either criterion or both);
Platelet count <75,000/mm3(<75.0 × 109/L);
ALC <500/mm3(<0.5 × 109/L).
NOTE: Participants with ALC <500/mm3(0.5×109/L) will be reflex tested for 
FACS -TBNK until the ALC resolves or stabilizes at a level acceptable to the 
investigator and sponsor .
Creatine kinase >10 ×ULN .
NOTE: In addition to re -testing creatinine kinase >3 ×ULN, urine m yoglobin will 
be performed as reflex testing for any  participant with creatine kinase 
>10×ULN .

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 83AST or ALT that meet ANY of the following:
>[ADDRESS_1221122] one total bilirubin value >[ADDRESS_1221123];
>[ADDRESS_1221124] accompanied by  [CONTACT_78257] s ymptoms consistent with hepatic 
injury  (eg, new onset elevated PT/INR);
Two sequential AST or AL T elevations >[ADDRESS_1221125], regardless of total 
bilirubin or accompan ying signs or s ymptoms.
NOTE: In each case, there is a need for additional investigations, such as review of ethanol, 
recreational drug and dietary  supplement consumption; testing for acute hepatitis A, B or C 
infection a nd biliary  tract imaging should be promptly  discussed with the sponsor or 
designee.

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 8410.9. Appendix 9: Abbreviations
The following is a list of abbreviations that may  be used in the protocol.
Abbreviation Term
AA alopecia areata
Abs absolute
ADL activity  of daily  living
AE adverse event
ALC absolute ly mphocy te count
ALT alanine aminotransferase
ANC absolute neutrophil count
AST aspartate aminotransferase
AUC [ADDRESS_1221126] quantifiable concentration
AUC inf area under the plasma concentration -time profile from time 
0extrapolated to infinite time
AV atrioventricular
-hCG beta-human c horionic gonadotropin
bpm beats per minute
BA bioavailability
BAEP Brainstem auditory  evoked potentials
BID twice a day
BMI body  mass index
BP blood pressure
BUN blood urea nitrogen
CD Crohn’s Disease
CFR Code of Federal Regulations
CI confidence interval
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
CKD -EPI [INVESTIGATOR_874382]/F apparent clearance
Cmax maximum observed plasma concentration
CNS central nervous s ystem
CO 2 carbon dioxide (bicarbonate)
COVID -[ADDRESS_1221127] research organization
CRU clinical research unit
C-SSRS Columbia -Suicide Severity  Rating Scale

Ritlecitinib ( PF-06651600 )
Protocol B798106 [ADDRESS_1221128] in human
FSH follicle -stimulating hormone
FU follow -up
GCP Good Clinical Practice
GFR glomerular filtration rate
GGT gamma -glutamy l transferase
HCVAb hepatitis C antibody
HDL high-densit y lipoprotein
HepBcAb hepatitis B core antibody
HepBsAb hepatitis B surface antibody
HepBsAg hepatitis B surface antigen
HIV human immunodeficiency virus
HR heart rate
HRT hormone replacement therap y
IB Investigator’s Brochure
ICD informed consent document
ICH International Council for Harmonisation
IGRA Interferon Gamma Release Assay
IL interleukin
INR international normalized ratio
IQMP Integrated Quality  Management Plan
IRB Institutional Review Board

Ritlecitinib ( PF-06651600 )
Protocol B798106 [ADDRESS_1221129] level
PCRU [COMPANY_007] Clinical Research Unit
PGx pharmacogenomics
PI [INVESTIGATOR_874383](s)
PNS peripheral nervous s ystem
PR the period that extends from the beginning of the P wave until the 
beginning of the QRS complex
PT prothrombin time
PVCs premature ventricular contractions
PXR pregnane X receptor
QD once daily
QT time from the beginning of the QRS complex to the end of the T 
wave
QTc corrected QT interval
QTcF corrected QT c using (Fridericia method)
QTF -G QuantiFERON -TB Gold
qual qualitative
RA rheumatoid arthritis
RBC redblood cell
SAE serious adverse event
SAP Statistical Analysis Plan
SCr serum creatinine
SD single dose
SoA schedule of activities
SOP standard operating procedure
SRSD single reference safet y document
S[LOCATION_003]R suspected unexpected serious adverse reaction
t½: terminal half -life

Ritlecitinib ( PF-06651600 )
Protocol B798106 [ADDRESS_1221130] upper limit of normal
US [LOCATION_002]
USPI [INVESTIGATOR_185578] I nformation
Vz/F apparent volume of distribution following oral administration
WBC white blood cell
WOCBP woman of childbearing potential

Ritlecitinib ( PF-06651600 )
Protocol B798106 9
Final Protocol Amendment 1 , 17September 2021
PFIZER CONFIDENTIAL
Page 8811.REFERENCES
1Kliewer SA, Goodwin B, Willson TM. The nuclear pregnane X receptor: a key  regulator 
of xenobiotic metabolism. Endocr Rev 2002;23:687 –702.
2Back D J, Tjia J, Mönig H, et al. 
Selective inhibition of drug oxidation after 
simultaneous administration of two probe drugs, antipy rine and tolbutamide . Eur J Clin 
Pharmacol 1988;34(2):[ADDRESS_1221131] Dis Mar -Apr 
1990;[ADDRESS_1221132] 3:S327 -33.
4Viatris I nc. Tolbutamide Product Detail website. Available from: 
https://www.viatris.com/en -us/lm/country home/us -
products/productcatalog/productdetails?id=34d22324- 71e0 -45c7 -bc72 -6d30d2fd4ef2. 
Accessed: 15 Jun 2021.
5Daily Med. Tolbutamide Tablet Drug Label Information website. Available from: 
https://daily med.nlm.nih.go v/dail ymed/drugInfo.cfm?setid=3995eed8
-39ec -ce5e-8cc2 -
062f93445c8d. Accessed: 15 Jun 2021.
6Veronese M E , Miners J O, Randles D, et al .Validation of the tolbutamide metabolic 
ratio for population screening with use of sulfaphenazole to produce model phen otypic 
poor metabolizers
. Clin Pharmacol Ther 1990 Mar;47(3):[ADDRESS_1221133] of genot ype and enzyme 
induction on the metabolic capacity  of CYP2C9 in healthy  volunteers. Clin Pharmacol 
Ther 2009 Jul;86(1):54 -61.
8Gillen M, Yang C, Wilson D, et al. Evaluation of pharmacokinetic interactions between 
lesinurad, a 
new selective urate reabsorption inhibitor, and CYP enzyme substrates 
sildenafil, amlodipi[INVESTIGATOR_050], tolbutamide, and repaglinide. Clin Pharmacol Drug Dev 2017 
Jul;6(4):363-76.
9Perkins, E, Posada, M, Kellie Turner, P , et al. Physiologicall y Based pharmacokinetic 
modelling of 
cytochrome P450 2C9 -related t olbutamide drug interactions with 
sulfaphenazole and t
asisulam. Eur J Drug Metab Pharmacokinet 2018; 43(3): 355–67.
10Gross AS, Bridge S, GM. Pharmacokinetics of tolbutamide in ethnic Chinese. Shenfield 
Br J Clin Pharmacol 1999;47(2):151
-6                                                
